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ABSTRACT 
 
BACKGROUND: Prion diseases, such as bovine spongiform encephalopathies (BSE), 
are transmissible neurodegenerative disorders affecting humans and a wide variety of 
mammals. Variant Creutzfeldt-Jakob disease (vCJD), a prion disease in humans, has 
been linked to exposure to BSE prions. This classical BSE (cBSE) is now rapidly 
disappearing as a result of appropriate measures to control animal feeding and 
monitoring. Besides cBSE, two atypical forms (named H- and L-type BSE) have recently 
been described in Europe, Japan, and North America. Here we describe the first wide-
spectrum microarray analysis in whole blood of atypical BSE-infected cattle. 
Transcriptome changes in infected animals were analyzed prior to and after the onset of 
clinical signs. Some of the most significant differentially expressed genes (DEGs) were 
validated by quantitative real time PCR (RT-qPCR).  
AIM: The aim of this study was to analyze the transcriptome changes in whole blood 
from atypical BSE-infected animals prior and after the onset of the clinical signs to 
understand the peripheral mechanisms of prion infection and to line out some candidate 
genes that could be further investigated as biomarker of the disease. 
METHODS: Total RNA from whole blood samples from 8 intracranially BSE-challenged 
cattle (4 with H-type and 4 with L-type BSE) and 2 non-infected age- and sex-matched 
controls was isolated and subjected to the microarray analysis using the GeneChip® 
Bovine Genome Array (Affymetrix). In order to increase the animal cohort, RNA 
samples from four additional sex-matched control cattle were isolated using the same 
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protocol as the original study group and included in the final statistical analysis. 
Therefore, 24 RNA samples, divided in 8 preclinical (P1, P2, P4, P5, P7, P8, EP9 and 
P10), 8 clinical (S1, S2, S3, S4, S7, S8, S9 and S10), and 8 control (c2, c3, cP3, c5, 
cS5, cP6, cS6 and c9) samples, constituted our animal cohort. After the assessment 
and inspection of microarray quality controls (RNA degradation plot, RLE and NUSE 
plots) we identified one low quality control sample (cS5) and excluded it from the final 
statistical analysis. Gene probes with a p value ≤0.05 and fold-change ≥2 were 
considered to be differentially expressed. To confirm the microarray results, we 
performed RT-qPCR using SYBR® green assay (Bio-Rad Laboratories, Inc.) for a 
selected number of target genes. The RT-qPCR analysis was performed on 22 samples 
(7 control, 8 preclinical and 7 clinical animals). The normalization accuracy was 
improved by geometric averaging of multiple reference genes (GAPDH, RPL12 and 
ACTB) and using two inter-run calibrators to reduce inter-run variation.  
RESULTS: The microarray analysis revealed a total of 101 differentially regulated probe 
sets (p value lower than 0.05 and changes in expression higher than 2-fold) in infected 
animals (clinical and preclinical) versus control group. In the clinical stage, a total of 207 
probe sets showed significant alteration in expression levels compared to the control 
group. Interestingly, a pronounced alteration in the gene expression profile was also 
found in the preclinical stage, with a total number of 113 differentially expressed probe 
sets. A set of 35 differentially expressed genes was found to be in common between 
clinical and preclinical stages and showed a very similar expression pattern in the two 
phases. To further dissect gene expression alterations during the progression of the 
disease, we performed a statistical analysis to identify specific changes between the 
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clinical and preclinical stages (CvsP). Indeed, we found 235 DEGs, which were 
significantly enriched in pathways related to immune response. The comparison of all 
the analysis, revealed a 22-gene signature with an up/down-down/up pattern of 
expression, being differentially expressed in preclinical stage and then going back to 
control levels in the symptomatic phase. One gene, SEL1L3, was progressively 
downregulated during the progression of the disease. The identified genes belong to 
several pathways, such as immune response and metabolism, that may play an 
important role in prion pathogenesis. The RT-qPCR analysis confirmed the microarray 
results for six out of nine genes selected (XIST, CD40L, GNLY, PDK4, HBA2 and 
SEL1L3). 
CONCLUSIONS: The present study has led to the identification of several gene 
expression changes in whole blood from atypical BSE infected cattle prior and after the 
manifestation of the pathology. Our findings suggest that it might be feasible to use 
whole blood RNA transcriptional profiles to distinguish between preclinical and clinical 
stages of prion infection. Overall, our study confirmed the differential expression of 6 
genes (XIST, CD40L, GNLY, PDK4, HBA2 and SEL1L3), which may play several roles 
in atypical BSE pathogenesis and, possibly, in other prion infections. Even though 
further studies are required to investigate the specific involvement of all the identified 
genes in prion diseases, our data support the idea of a relationship of complicity and 
blindness between prion and the host immune system. As concluding remark, our study 
underlined the importance of utilizing whole blood, without any additional manipulation, 
as a source tissue for the development of a preclinical diagnostic test. 
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1. Introduction 
Prion diseases are a group of fatal neurodegenerative disorders which affect humans 
and a wide variety of mammals. These pathologies are characterized by various 
neurological dysfunctions and share common histopathological features including 
neuronal cell loss, spongiform lesions in the brain, astrogliosis and accumulation of 
misfolded prion protein. Among the various neurodegenerative illnesses, prion diseases 
are peculiar in that their etiology, besides being sporadic and genetic, may also be 
infectious. Although such pathologies in humans are fairly rare (worldwide incidence of 
1 case/million people every year), they have attracted great interest from the scientific 
community and general society for two main reasons: first, because of the bovine 
spongiform encephalopathy (BSE) epidemic in United Kingdom (UK) in 1992 and the 
growing body of evidence associating a new variant of Creutzfeldt-Jakob Disease 
(vCJD) with the consumption of BSE-infected meat and bone meal. Second, because of 
the unprecedented findings linked to the prion field which revolutionized some of the 
most important dogma in biology. Such findings include: 1) disease transmission 
through proteinaceous material, in the absence of any nucleic acid; 2) the presence of 
several different folding conformations associated with one protein, each with distinct 
biological properties; and 3) the transmission of biological information by the replication 
of protein conformation (Soto and Saborio 2001). Despite intense research, the 
molecular pathways leading to neurodegeneration in prion disease remain unknown and 
no effective treatments or ante-mortem diagnosis is currently available. 
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1.1 What is a prion 
 
Prion is a term coined in 1982 by Stanley B. Prusiner to describe a “proteinaceous 
infectious particle“, which was identified as the causative agent of several 
neurodegenerative diseases in mammals, collectively known as prion diseases or 
transmissible spongiform encephalopathies (TSEs). According to the “protein only 
hypothesis” formulated by Stanley B. Prusiner (Prusiner 1982), a prion is composed 
entirely of protein material which is able to replicate and transmit infection without the 
need of nucleic acids. Prions are highly resistant to ultraviolet and ionizing radiation, 
procedures that can destroy pathogens containing DNA or RNA. Other peculiar 
characteristics of prions are their insolubility in detergents and their resistance to 
proteinases. These latter features were exploited by Prusiner and colleagues to isolate 
a protein of 27-30 kDa from the brain of prion-infected Syrian hamsters (Prusiner, Groth 
et al. 1984). This protein was called PrPSc (from Scrapie Prion Protein). The subsequent 
sequencing of PrPSc led to the identification of an endogenous gene (PRNP in humans 
and Prnp in mice) whose product was called cellular prion protein (PrPC). Thus, this 
finding showed that PrPC and its infectious isoform PrPSc share the same primary 
sequence but a different conformation.  
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1.2 PrP
C 
and PrP
Sc
 structure 
 
As stated above, PrPC and PrPSc are different in respect to several characteristics, such 
as solubility, proteinase K resistance and other features. Despite these differences, 
PrPC and PrPSc share an identical primary structure whose sequence is coded by a 
gene found on chromosome 20 in humans, 13 in bovine and on chromosome 2 on mice. 
The entire open reading frame (ORF) of known mammalian and avian PrP genes is 
contained within a single exon. The two exons in, for example, Syrian hamster 
(SHa)PrP gene are separated by a 10-kb intron. The PrP genes of mouse, sheep, 
bovine and rat are constituted by 3 exons and the ORF lies entirely on exon 3 
analogous to exon 2 of SHa(PrP) gene (Westaway et al. 1991, 1994, 1994). Similarly to 
(SHa)PrP gene, in humans the gene encoded by PRNP contains two exons and the 
ORF is contained entirely within exon 2. The mature transcript is translated into a 253 
amino acid protein (254 in mice), which is post-translationally modified and shortened 
into a 209 amino acid-long protein (208 in mice). Limited proteolysis of PrPSc leads to 
the formation of PrP 27-30 fragment, which is composed of approximately 142 amino 
acids (Fig. 1). 
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Fig. 1: PRNP gene and prion protein isoforms. PRNP ORF encodes for a protein of 254 
residues that is post-translationally shortened to 209 residues, which constitute mature PrPC. 
PrPSc shares the same primary structure with PrPC but it is characterized by a different 
conformation. Limited proteolysis of PrPSc cleaves 67 amino acids from the amino terminus and 
produces PrP 27-30, composed of approximately 142 residues (adapted from (Colby and 
Prusiner 2011)). 
PrPC is constituted by an N-terminal unstructured region (residues 23-90) and a C-
terminal globular domain (residues 90-231) (Riek, Hornemann et al. 1997, Zahn, Liu et 
al. 2000). The N-terminal endoplasmic reticulum (ER) signal peptide (residues 1-22) is 
post-translationally cleaved during the maturation of the protein as well as the C-
terminal peptide 232-254, and it is modified by a GlycosylPhosphatidylInositol (GPI) 
anchor in position 231 that allows the insertion of the protein in the outer membrane 
(Riesner 2003). The flexible N-terminal “tail” contains two hexarepeats (HR, residues 
34–39 and 45–50) and an octapeptide domain (OR, residues 51–91). Up to four copper 
ions can be associated to the octapeptide region, with the higher affinity for Cu2+ 
(Hornshaw, McDermott et al. 1995, Stockel, Safar et al. 1998, Whittal, Ball et al. 2000). 
In addition, two histidine residues able to bind copper are found in the 92–111 region 
(non-octapeptide copper binding site). A hydrophobic core at position 113–135, together 
with the non-octapeptide binding region (92-111), constitutes the central domain of prion 
protein. Residues 129-133 and 160-163 constitute two β-strands folded into a small 
antiparallel β-sheet. A first alpha-helix (H1) is present between the two β-strands 
(residues 144-153) while the other two alpha-helices (H2 and H3, residues 166-194, 
200-226) form a two-helix bundle which is stabilized by a disulfide bond between Cys 
179 and Cys 214 (Turk, Teplow et al. 1988). Finally, at position 180 and 196 a 
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consensus sequence for Asn-linked glycosylation is present, giving rise to the di-, 
mono- and unglycosylated PrP (Stimson, Hope et al. 1999) (Fig. 2).  
 
A                                                                     B 
    
Fig 2. Amino acid sequence, post-translational modifications and 3D structure of prion protein.  
1–22, post-translationally cleaved ER signal peptide; 34–39 and 45–50, 2 hexarepeats; 51–91, 5 
octarepeats; 95-110, charged cluster; 113–128, conserved hydrophobic region; 121–231, hamster PrP
C
 
C-terminal globular domain; 129-133, β-strand 1; 145–153/155, α-helix 1; 160–163, β-strand 2; 166–194, 
α-helix 2; 179/214, disulfide bridge; 180/181, N-glycosylation 1 in mouse/human; 196/197, N-glycosylation 
2 in mouse/human; 200–226, α-helix 3; 231, GPI-anchor; 232–254, GPI signal peptide (cleaved). 
Positively charged amino acids (at pH 7) in red, negatively charged in blue, neutral in magenta, 
hydrophobic in brown (from Riesner D., 2003)(A). Tertiary structure of the cellular prion protein inserted 
into a lipid bilayer, as deduced from NMR spectroscopy, including the 'unstructured' N-terminal tail (grey) 
and the glycosyl phosphatidyl inositol (GPI) anchor. The loop connecting the second beta-sheet and the 
third alpha-helix is indicated by the black arrow. OR, octarepeat region (adapted from Aguzzi A. et al., 
2006) (B). 
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Unlike PrPC, PrPSc structure has not been elucidated yet, since its insolubility does not 
allow the access to structural analysis by nuclear magnetic resonance (NMR) or X-ray. 
Circular dichroism and infrared spectroscopy analysis have revealed that while PrPC is 
constituted by a high content of α-helix (40% of the protein) and a small percentage of 
of β-sheet (3% of the protein), PrPSc instead is characterized by an higher content of β-
sheet (45% of the protein) and less α-helix (30% of the protein) (Caughey, Dong et al. 
1991, Safar, Roller et al. 1993). In electron micrographs, PrPSc is visible as fibrillar 
structures and staining with Congo red shows the typical fluorescence associated to 
amyloid fibrils.  
1.3 Conversion of PrP
C
 into PrP
Sc 
 
Studies on Prnp knock-out (KO) mice (also indicated as Prnp-/- mice) showed that the 
presence of endogenous PrP is necessary to sustain prion infection. Indeed, mice 
lacking PrPC are resistant to infection and unable to generate infectious particles 
(Bueler, Aguzzi et al. 1993). These findings suggested that the prion replication process 
is based on the ability of PrPSc to replicate itself by transferring its toxic conformation to 
the host PrPC. Molecular studies and in vitro prion replication analysis suggested the 
existence of a chaperone-like protein (designated as protein X), which could facilitate 
the structural conversion (Telling, Scott et al. 1995, Saborio, Soto et al. 1999). At 
present the nature of this protein remains unknown. Assuming the prion-only 
hypothesis, up to now two main models for PrPC conversion into PrPSc have been 
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postulated (Fig. 3): the “template-assisted model” and the “nucleation model” (Cohen 
and Prusiner 1998, Aguzzi, Montrasio et al. 2001). 
  
According to the template-assisted model (or refolding model) a high-energy barrier 
might prevent spontaneous conversion of PrPC into PrPSc. Therefore, a physical 
interaction between exogenous prion and endogenous PrP would allow the conversion 
process (Fig 3a). On the contrary, the nucleation or “seeding” model proposes a 
reversible thermodynamic equilibrium between PrPC and PrPSc conformations, with PrPC 
being more stable. Only the presence of several PrPSc molecules disposed into an 
ordered seed would shift the balance toward the PrPSc conformation. In this way new 
monomeric PrPSc molecules would be recruited to form oligomeric and fibrillary amyloid 
structures (Fig. 3b). 
  
Fig. 3. Model for conversion of PrP
C
 
into PrP
Sc
. The template-assisted model, 
or refolding model, argues that PrP
C 
is 
separated from PrP
Sc
 by a high energy 
barrier, which prevents a spontaneous 
conversion. Exogenous administration of 
PrP
Sc 
acts as a catalyst and lowers the 
energy barrier. In addition, each prion 
strain acts as a unique template 
providing conformational constrains (a). 
According to the “seeding” model, the 
rate-limiting step is the formation of a 
seed: an oligomeric aggregate of PrP 
which is thermodynamically unstable and 
shifts the balance toward PrP
Sc
 formation 
(b). (Aguzzi et al., 2001). 
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1.4 Prion diseases  
 
1.4.1 Human TSEs 
 
Human TSEs include Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-
Scheinker syndrome (GSS), kuru, fatal familial insomnia (FFI), PrP cerebral amyloid 
angiopathy (PrP-CAA) and variably protease-sensitive prionopathy (VPSPr). Unique 
among all the neurodegenerative disorders, prion diseases, in addition to being 
sporadic and genetic, can also be acquired. Acquired prion diseases arise from 
accidental exposure to prions through medical procedures, such as in iatrogenic CJD 
(iCJD), or from consumption of infected meat, as in variant vCJD and kuru. Sporadic 
TSEs are the most common, while genetic forms represent approximately 10% of the 
total number of prion disease cases (Mastrianni 2010). Genetic prion diseases are 
inherited in an autosomal dominant pattern and have a slightly earlier age at onset and 
a slower course. All mutations associated to genetic prion disorders are found on the 
PRNP gene. Recent findings indicate that the PrP genotype and the PrPSc type have a 
major influence on the disease phenotype (Gambetti, Kong et al. 2003).  
1.4.1.1 CJD 
 
CJD, also denoted as classical CJD (cCJD), is the most common human prion disease, 
although it is still rare. The sporadic forms of CJD (sCJD) are the most common, 
accounting for >80% of all human prion diseases, with an incidence of one per one 
million people every year. Familial CJD (fCJD) cases represent 5% to 15% of the total 
number of CJD cases and are all caused by mutation in the ORF of PRNP. Acquired 
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forms of CJD are constituted by iatrogenic CJD (iCJD) and variant CJD (vCJD). vCJD 
will be discussed in detail later in the text. Concerning iCJD, it account for less than 1% 
of all CJD cases. iCJD are due to accidental transmission via contaminated 
neurosurgical instruments, brains derivatives such as infected cadaveric human growth 
hormone (used prior to 1980, over 200 cases largely in France), corneal transplantation 
and dura mater graft (over 200 cases, largely in Japan). CJD pathology is characterized 
by rapidly progressive dementia, memory loss, personality changes, hallucinations, 
speech impairment, myoclonus, ataxia, seizures and changes in gait. Involuntary 
movements follow in most patients with these symptoms. The duration of the disease 
varies greatly. However, in most cases affected people die in the first year after the 
appearance of the main symptoms. Polymorphism at codon 129 (methionine or valine) 
and the type (type 1 or 2) of PrPSc have been recognized as major determinants of the 
clinical features and, as regards polymorphism at codon 129, as a genetic marker for 
susceptibility to CJD in the Caucasians (Mitrová, Mayer et al. 2005). Methionine 
homozygosity (M/M) has been identified in 70–74% of cases of sporadic sCJD 
(Laplanche, Delasnerie-Laupretre et al. 1994) and in 78.6% of patients suffering from 
fCJD carrying E200K mutation (Mitrova and Belay 2002). 
1.4.1.2 vCJD 
 
Foodborne transmission of BSE prions to humans was observed in the 1990s with the 
appearance of a new variant form of CJD (vCJD) (Will, Ironside et al. 1996). A link 
between vCJD and BSE was first hypothesized because of the association of these two 
TSEs in time and place. Further, it has been shown experimentally that BSE prions 
have strain characteristics identical to those of prion isolates from human cases of vCJD 
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(Bruce, Will et al. 1997). So far, 229 cases of vCJD have been reported worldwide 
(http://www.cjd.ed.ac.uk/documents/worldfigs.pdf). Although there is an overlap of 
clinical characteristics, vCJD cases are a distinct group respect to classical CJD. In 
contrast to the traditional forms of CJD, vCJD has affected younger patients (median 
age at death of 28 years, as opposed to 68 years) and it has a relatively longer duration 
of illness (median of 14 months as opposed to 4.5 months). Most people who have 
developed vCJD lived in the UK or were exposed to the BSE while residing in the UK. 
Past surgery or blood transfusion is not a risk factor. However, four cases were 
observed in patients who received blood from individuals that later were diagnosed as 
vCJD (Llewelyn, Hewitt et al. 2004, Peden, Head et al. 2004, Wroe, Pal et al. 2006) 
(see paragraph 1.9).  
During the early stage of the disease, vCJD patients present psychiatric symptoms. The 
first neurological signs appear after 6 months, and include ataxia, cognitive impairment 
and involuntary movements. After a progressive neurological deterioration patients 
become mute, incontinent and bed-bound. Death is often due to intercurrent infection 
(Will 2003). M/M homozygosity was found in all tested cases of vCJD identified to date 
compared to about 39% of the general Caucasian population (Will, Ironside et al. 1996). 
A reduced frequency of HLA class II type DQ7 has been described in patients with 
vCJD but not in those with sCJD. The molecular basis of the protective association of 
DQ7 and vCJD is unknown. Class II molecules of the major histocompatibility complex 
(MHC) may have a direct role in disease pathogenesis, or a gene linked to the DQB 
locus may be involved (Jackson, Beck et al. 2001).  
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1.4.1.3 Gerstmann-Sträussler-Scheinker syndrome (GSS) 
 
Differently from CJD, GSS is exclusively genetic. The precise incidence is unknown, but 
is estimated around 5 cases per 100 million inhabitants per year (Ribosa-Nogué, 
Pagonabarraga et al. 2016). It is characterized by dysarthria and slowly progressive 
cerebellar ataxia followed by dementia. In some cases loss of memory is the first sign of 
GSS. Extrapyramidal motor disturbances are common and they manifest as myoclonus, 
athetosis and rigidity. All GSS patients present widespread multicentric amyloid plaques 
in the brain. GSS is the slowest to progress among human prion diseases. Duration of 
illness can range from 3 months to 13 years. The most common GSS causal mutation 
consists in the substitution of a proline in position 102 of the ORF of PRNP to a leucine 
(P102L). Even if GSS is classified as transmissible disease, it has been shown that in 
patients carrying P102L mutation the pathology is transmissible in just 40% of the cases 
(Collins, McLean et al. 2001). The rest of the mutations are very rare and in the majority 
of the cases the associated GSS pathology cannot be transmitted in primates and 
rodents. A recent study published by Laura Pirisinu and colleagues, conclusively 
showed that GSS with P102L, A117V and F198S mutations can be transmitted 
efficiently and produces distinct pathological phenotypes in bank voles (Pirisinu, Di Bari 
et al. 2016).  
1.4.1.4 Fatal Familial Insomnia (FFI) 
 
As with GSS, FFI is almost invariably genetically determined, though sporadic forms 
have been described. Most genetic cases are linked to a mutation at codon 178 of 
PRNP causing substitution of asparagine to aspartic acid (D178N). This mutation is 
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found also in fCJD patients. However, FFI is associated with D178N mutation combined 
in cis with methionine at codon 129 (D178N–129M), whereas fCJD is linked to the 
presence of valine (D178N–129V) (Goldfarb, Petersen et al. 1992). The brain of typical 
D178N FFI patients shows a characteristic restricted degeneration, largely confined to 
the thalamus. The presentation of the disease varies considerably from person to 
person. The main symptom is a progressively worsening insomnia, which leads to 
hallucinations, delirium, loss of weight and dementia.  
1.4.1.5 Kuru 
 
Kuru came to the attention of medicine in the mid-1950s when remote parts of New 
Guinea were explored by Australian administrators. Clinical hallmarks of the disorder 
consist of cerebellar ataxia and body tremors, as well as uncontrolled laugh. The 
preclinical phase lasts between 5 to 20 years following initial exposure, while the clinical 
stage lasts an average of 12 months. It is now widely accepted that kuru was 
transmitted among members of the Fore tribe of Papua New Guinea via funerary 
cannibalism, becoming endemic amongst these populations since 1941 (Gajdusek and 
Reid 1961). Although the ultimate cause of kuru remains uncertain, a cannibalistic serial 
passage of a sporadic case of indigenous CJD remains the most plausible hypothesis 
(Gajdusek 1977).  
1.4.1.6 PrP Cerebral amyloid angiopathy (PrP-CAA).  
 
PrP-CAA is a rare form of genetic prion pathology characterized by neurofibrillary 
tangles and PrP-positive amyloid fibril deposits in arteries and arterioles walls.  PrP-
CAA, without co-localization of Aβ (deposition of Aβ in blood vessels is the most 
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common cause of CAA in humans), has thus far only been described  in two patients 
with nonsense mutations at codon 145 (Y145X) or 163 (Y163X) of PRNP (Jansen, 
Parchi et al. 2010). Both stop mutations lead to the loss of the GPI anchor, required to 
attach the protein to the outer leaflet of the plasma membrane. This suggests that the 
GPI moiety might interfere with the ability of PrP to form amyloid fibrils and when it is 
absent PrP readily aggregates, resulting in cerebrovascular amyloid deposition 
(Chesebro, Trifilo et al. 2005, Revesz, Holton et al. 2009).  
1.4.1.7 Variably Protease-Sensitive Prionopathy (VPSPr) 
 
In 2008, a novel prion disease, initially referred to as protease-sensitive prionopathy, 
was reported in 11 patients. All of them had the 129VV genotype, and presented no 
mutations in the PRNP gene. Brain examination revealed a peculiar accumulation of 
micro plaques within the cerebellum and thalamus. The defining feature of this group of 
patients was the unusual biochemical properties of the abnormal PrP in the brain. The 
PrPSc in VPSPr was found to be much less resistant to protease digestion compared to 
PrPSc from sCJD, and presented a prominent low–molecular weight fragment of ≈8 kDa. 
Subsequently, 19 additional cases have been reported, including some in patients with 
129MM and 129MV genotypes (Diack, Ritchie et al. 2014). Patients show psychiatric 
symptoms, speech deficits (aphasia and/or dysarthria), and cognitive impairment. In the 
129VV genotype, which is present in around 65% of total VPSPr cases, the first clinical 
symptoms are mood and behavior changes, speech deficit and cognitive impairment, 
while 129MV and 129 MM genotype (≈23% and ≈12%, respectively) often present with 
parkinsonism followed by ataxia, myoclonus and progressive cognitive impairment. The 
common hallmark to all genotypes at codon 129 is the presence of moderate 
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spongiform degeneration comprising of vacuoles in the major cerebral regions (Zou, 
Puoti et al. 2010). 
1.4.2 Animal TSEs 
 
Animal prion diseases include scrapie in sheep and goats, bovine spongiform 
encephalopathy (BSE), transmissible mink encephalopathy (TME), feline spongiform 
encephalopathy (FSE), exotic ungulate spongiform encephalopathy (EUSE), chronic 
wasting disease (CWD) in cervids and spongiform encephalopathy of non-human 
primates. In the majority of the cases, animal TSEs derive from ingestion of 
contaminated feed or exposure to contaminated environment. In the following 
paragraphs a brief description of each animal TSE will be provided. 
1.4.2.1 Classical and Atypical BSE 
 
Classical BSE (cBSE), commonly known as "mad cow disease", is a TSE found in 
cattle, which became epidemic in the UK in 1986-98. More than 180,000 cattle were 
infected and 4.4 million slaughtered during the eradication program. The pathology 
presents with tremors, gait abnormalities, difficultly in raising or walking, aggressive 
behavior, apprehension, and hyperreactivity to stimuli. PrPSc accumulation can be 
observed in brain tissues as early as 2 years post inoculation in experimental cases. 
The incubation period for BSE ranges from 2 to 8 years and most BSE cases have been 
found in 4 to 5 year old dairy cattle. Besides cBSE, in recent years two atypical forms of 
BSE have been identified in several European countries (Jacobs, Langeveld et al. 
2007), Japan (Yamakawa, Hagiwara et al. 2003, Masujin, Shu et al. 2008), United 
States (Richt, Kunkle et al. 2007) and Canada (Dudas, Yang et al. 2010). The two 
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atypical BSE strains are denoted as H-type BSE and L-type BSE (also named bovine 
amyloidotic spongiform encephalopathy, BASE) (Casalone, Zanusso et al. 2004, 
Beringue, Andreoletti et al. 2007). The “H” and “L” identify the higher and lower 
electrophoretic mobility of the unglycosylated protease resistant PrPSc fragment, 
respectively (Biacabe, Laplanche et al. 2004) (Fig. 4).  
 
Both atypical forms, but especially the L type, were further characterized by a smaller 
proportion of diglycosylated PrPSc compared to the proportion in cBSE isolates. In 
addition to the migration properties and glycosylation profiles, the H- and L-type isolates 
exhibited enhanced PK sensitivity at pH 8 compared to those of the cBSE isolates 
(Jacobs, Langeveld et al. 2007). So far, both atypical subtypes have been identified only 
in cattle that were at least eight years old (Tester, Juillerat et al. 2009). It has therefore 
been postulated that they represent a spontaneous TSE in cattle, although transmission 
through feed or the environment cannot be ruled out. Histopathological as well as 
immunohistochemical analyses show that atypical forms of BSE can be experimentally 
transmitted to transgenic mice and primates and clearly differ from cBSE isolates, with 
unique incubation periods, PrPSc profiles, and histological lesions (Buschmann, 
Gretzschel et al. 2006, Baron, Bencsik et al. 2007, Comoy, Casalone et al. 2008, 
Wilson, Dobie et al. 2013). However, some recent studies showed that H- and L-type 
Fig. 4.  PrP
Sc
 electrophoretic mobility after PK 
digestion in classical and atypical BSE. From the 
left: classical BSE, L-type BSE and H-type BSE 
banding in canonical western blot analysis after PK 
digestion (Gough, Rees et al. 2015).  
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BSE prions may acquire cBSE–like properties during propagation in animals expressing 
homologous bovine prion protein (Torres, Andreoletti et al. 2011) or during inter-species 
transmission (Beringue, Andreoletti et al. 2007), respectively. Moreover, transmission 
experiments in transgenic mice and macaque have revealed clear indications for a 
higher zoonotic potential of this BSE form than classical BSE (Buschmann, Gretzschel 
et al. 2006, Comoy, Casalone et al. 2008, Kong, Zheng et al. 2008). 
1.4.2.2 Scrapie 
 
Scrapie is the ancient form of TSE and has sheep and goats as natural target species. 
The clinical features of this pathology are dependent on the prion strain and the animals' 
genetic background. The most common symptom is intense pruritus which leads to 
rubbing and scraping and subsequent loss of wool. This is associated to the 
characteristic nibbling response when pressure over the base of the tail or scratching to 
the dorsum is applied. Other symptoms could include behavioral changes, blindness, 
ataxia, incoordination, hyperexcitability and tremors. Incubation period is 2-5 years and 
death usually occurs within 2 weeks to 6 months after clinical onset. About 3-5% 
animals per affected flock may die annually (Jeffrey and Gonzalez 2007). In cases of 
atypical scrapie, pruritus is uncommon, while the major symptoms are ataxia and 
incoordination. Other signs include irritability, unusual alertness, restlessness, impaired 
vision, hyperesthesia, posture abnormalities, tremors, teeth grinding, and salivation 
(Benestad, Arsac et al. 2008). Several polymorphisms in PRNP have been associated 
to scrapie susceptibility in goat and sheep. For example, Q171R and A136V 
polymorphisms confer resistance and susceptibility to the infection, respectively. A three 
codon system based on A136V, R154H and Q171R/H polymorphisms has been 
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characterized with five alleles (ARQ, VRQ, AHQ, ARR and ARH) which can be 
combined to form 15 genotypes, i.e. ARR/ARR or VRQ/ARQ (Hussain, Babar et al. 
2011). In turn, these 15 genotypes can be combined into five risk groups (R1-R5). The 
most resistant R1 genotype is ARR/ARR and the most susceptible R5 genotypes are 
VRQ/VRQ, VRQ/ARQ, VRQ/ARH and VRQ/AHQ. The remaining genotypes are of 
intermediary susceptibility (Imran and Mahmood 2011). This risk classification system 
was useful for many European states in selective breeding of sheep.  
1.4.2.3 Transmissible Mink Encephalopathy (TME) 
 
TME is a rare TSE of farmed mink. At clinical level the pathology is characterized by 
behavioral changes such as increased aggressiveness and hyperesthesia, depression, 
restlessness, and neglect in parental care and coat grooming. At the earlier disease 
stages, difficulty in eating and swallowing can also be observed. In the final stage of the 
disease, convulsions may occur; minks become somnolent and unresponsive, and can 
be seen to press their heads against the cage for hours. Inoculation of mink with various 
strains of the scrapie agent as well as inoculation with the classical BSE agent revealed 
the development of TME. Some studies suggested the atypical L-type BSE agent as the 
most likely candidate for being causative of TME (Baron, Bencsik et al. 2007).  
1.4.2.4 Chronic Wasting Disease (CWD) 
 
CWD is a TSE of captive and free-ranging members of the family Cervidae. Prevalence 
of the disease in affected herds may range from 0.1 to 50% or even 100%, sometimes. 
Chronic wasting is very common in affected cervids. Rough, dry coat and patchy 
retention of the winter coat in summer are also common. During the preclinical phase 
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some signs can be seen in affected cervids, such as lassitude, sudden death in deer 
after handling, a lowered head and drooping ears and behavioral changes such as fixed 
gaze and loss of fear of humans. Ataxia, head tremors, teeth grinding, hyperexcitability 
with handling and excessive salivation are some of the symptoms that can be observed 
during the clinical phase of the disease. Incubation time ranges from 16 months to 5 
years. Death usually occurs 1 year after the onset of clinical signs (Imran and Mahmood 
2011). 
1.4.2.5 Exotic Ungulate Encephalopathy (EUE) 
  
EUE is a TSE of exotic zoo ruminants of the family Bovidae. All infected animals died 
during the 1990s, with the last death occurring in 1998. The course of EUE and clinical 
symptoms varied, according to the species. It seems that these animals were infected 
through the consumption of meat and bone meal derived from BSE-infected cow. 
Indeed, similar neuropathological lesions and incubation periods were observed in mice 
inoculated with brain homogenates from EUE-infected ruminants and from BSE-infected 
cattle. Further, a similarity between the EUE and BSE strains in these mice was 
observed, supporting the hypothesis that EUE is caused by an infection with BSE prion.  
1.4.2.6 Feline Spongiform Encephalopathy (FSE) 
 
FSE is a TSE of domestic cats and captive wild members of the family Felidae. This 
disease was first reported in domestic cats within the United Kingdom in 1990. As most 
of the FSE cases occurred in parallel to the BSE epidemic, interspecies transmission 
via consumption of contaminated food was considered as causative of the disease. 
Indeed, mice infected with brain homogenate from BSE-infected cattle and from FSE-
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infected cats developed a very similar pathology and presented similar prion strains 
(Eiden, Hoffmann et al. 2010). With a ban on the use of bovine spleen and central 
nervous system (CNS) tissue as pet feed, the FSE epidemic declined rapidly. The 
clinical manifestation of the disease includes severe behavioral changes (fear, 
aggressiveness or unusual timidity), depression, restlessness, abnormal gait and ataxia. 
In addition, excessive salivation, polyphagia, polydipsia and dilated pupils have been 
reported as symptoms of FSE. In the final stages of the disease convulsions and 
somnolence are common signs. Death occurs after 3-8 and 8-10 weeks of clinical onset 
of the disease in domestic cats and cheetahs, respectively (Sigurdson and Miller 2003).  
1.4.2.7 TSE in Non Human Primates (NHP) 
 
TSE in NHP was observed from 1996 to 1999 in Mayotte lemurs, mongoose lemurs and 
Rhesus macaque from a zoo and three primate facilities in France. As for other animal 
TSEs, also in this case the most probable cause of the infection was the ingestion of 
feed contaminated with BSE-prions. Indeed, lemurs experimentally inoculated with brain 
homogenates from BSE-infected cattle developed a TSE with profiles of 
neuropathological lesions similar to those seen in naturally infected lemurs and 
presented similar prion strains (Bons, Mestre-Frances et al. 1999, Imran and Mahmood 
2011). 
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1.5 PrP
C
 physiological functions 
 
PrPC is a ubiquitous protein highly conserved among mammals and also expressed in 
other species such as fish, reptiles and birds. It is found predominantly in the CNS 
during embryogenesis and in adult life, but it is also highly abundant in the 
lymphoreticular tissues such as lymph nodes and spleen. In the CNS, PrPC is 
prevalently expressed in neurons of the cerebellum, cerebral cortex, hippocampus, 
medulla oblongata, and thalamus. Its prevalent synaptic localization suggests an 
involvement in synaptic signaling and in the neurotransmitter system of the CNS 
(Collinge, Whittington et al. 1994, Sales, Rodolfo et al. 1998). Although most PrPC is 
found in lipid rafts, some of the protein is transferred to clathrin-coated pits where is 
subjected to constitutive endocytosis and recycling (Naslavsky, Stein et al. 1997, 
Sunyach, Jen et al. 2003, Westergard, Christensen et al. 2007). The endocytic recycling 
pathway followed by PrPC and its affinity for Cu2+ suggests a possible role in copper 
metabolism (Brown, Qin et al. 1997, Stockel, Safar et al. 1998, Millhauser 2007). For 
PrPC many other possible biological functions have been suggested: cell adhesion, 
myelin maintenance, neurite outgrowth, antiapoptotic activity, and oxidative stress 
protection (Westergard, Christensen et al. 2007). Despite being one of the most 
intensively studied proteins, a definite role for PrPC has not been clarified yet and 
constitutes one of the main challenge in prion biology. The possible functions of PrP in 
the immune system will be discussed in detail later in this text (see paragraph 1.7). 
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1.6 PrP
Sc
 pathological functions 
 
In the prion field great effort has been made to understand the mechanisms of 
conversion and infectivity while much less attention has been posed on the mechanism 
by which prions cause the CNS pathology. How do prions exert their pathological 
effect? There are three main hypotheses explaining how the conversion of PrPC into 
PrPSc may cause neurodegeneration in the CNS:  
1) GAIN OF FUNCTION- According to this view, PrPSc would acquire new properties 
which are different from those related to the normal, physiological function of PrPC 
(Fig. 5A). This toxic gain of function could be related to the activation of different 
interactors and signaling pathways or to the general impairment of cell homeostasis. 
For example, PrP amyloid fibrils may block the normal neuronal transport, interfere 
with axonal signaling or physically damage neuronal membranes (Ermolayev, 
Friedrich et al. 2009, Senatore, Restelli et al. 2013). 
2) LOSS OF FUNCTION- This hypothesis postulates that upon conversion to or 
contact with PrPSc, PrPC would lose all or some of its putative biological functions, 
thus resulting in neuronal damage and degeneration (Fig. 5B). However, several 
lines of experiments using PrP-KO prenatal or postnatal mice models showed a very 
slight effect on the phenotype and no features of prion pathology (Bueler, Fischer et 
al. 1992, Manson, Clarke et al. 1994, Mallucci, Ratte et al. 2002). Thus, loss of PrPC 
function is not responsible, alone, for prion-induced neurodegeneration. The 
dominant inheritance of familial prion disease also belies the loss of function 
hypothesis. As an alternative, it is possible that the pathology caused by toxic gain of 
function would be exacerbated by a loss of function mechanism. 
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3) SUBVERSION OF FUNCTION- An intriguing possibility is that PrPSc subverts or 
alters the physiological function of PrPC, rather than causing a complete loss of 
function. This effect could be produced by crosslinking of PrPSc to PrPC and the 
subsequent activation of neurotoxic signaling pathways (Solforosi, Criado et al. 
2004) (Fig. 5C). Consistent with this theory, experimental evidence has shown that 
expression of PrPC in neurons is necessary to confer sensitivity to the infection 
(Brandner, Isenmann et al. 1996, Mallucci, Dickinson et al. 2003). GPI-anchoring 
appears to be required for such pathogenic mechanism, since anchorless prion 
protein results in infectious amyloid disease without clinical scrapie (Chesebro, Trifilo 
et al. 2005). How could PrPC functions be modified? A possibility is that PrPSc fibrils 
and oligomers would induce aggregation of cell surface PrPC, thereby generating a 
neurotoxic rather than a neuroprotective signal. Alternatively, PrPSc may bind 
specific PrPC domains thereby altering the signaling properties of the latter 
(Westergard, Christensen et al. 2007). 
 
 
 
Fig. 5. Models for the cellular toxicity of 
PrP
Sc
. Toxic gain-of-function: PrP
Sc 
possesses  a  novel  neurotoxic  activity  that  
is independent  of  the  normal  function  of  
PrP
C
 (A); Loss-of-function: PrP
C
 possesses  
a  normal,  physiological  activity that  is  lost  
upon  conversion  to  PrP
Sc
 (B); Subversion-
of-function: The  normal,  neuroprotective 
activity of PrP
C
 is subverted by binding to 
PrP
Sc
. From (Harris and True 2006). 
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1.7 PrP
C
 and the immune system 
 
For obvious reasons the majority of the research in the prion field has been focused on 
the pathophysiology of PrP in the CNS. However, PrPC is a protein expressed 
throughout the organism and it is selectively enriched and developmentally regulated in 
other cell types besides neurons (Linden, Martins et al. 2008). Importantly, lymphoid 
and myeloid tissues represent the second compartment, after the brain, where PrPC is 
most abundantly expressed (Ballerini, Gourdain et al. 2006). A substantial amount of 
PrPC has been found in human T and B lymphocytes, natural killer (NK) cells, platelets, 
monocytes, dendritic cells (DCs) and follicular dendritic cells (FDCs) as well as in 
hematopoietic stem cells (HSCs) (Dodelet and Cashman 1998, Barclay, Hope et al. 
1999, Burthem, Urban et al. 2001, Li, Liu et al. 2001, Thielen, Antoine et al. 2001, 
Isaacs, Jackson et al. 2006, Zhang, Steele et al. 2006). In addition, the immune system 
plays a fundamental role in prion pathology, since a substantial amplification of the 
infectious agent takes place within lymphoid compartments in early stages of the 
diseases (Aguzzi, Heppner et al. 2003, Linden, Martins et al. 2008). This process is 
dependent at least in part on expression of PrPC by certain immune cells (Brown, 
Stewart et al. 1999). However, as for the CNS, PrPC seems to be not strictly required for 
the normal physiology of the immune system. Indeed, no gross abnormalities were 
detected in PrP-KO mice, both in the numbers and maturation of the immune cells and 
in the expression of important cell surface antigens (Linden, Martins et al. 2008). In 
particular, PrP null mice displayed a normal number of dendritic, T CD4+, T CD8+ and 
B cells and had normal expression of MHC class I and II molecules (Bueler, Fischer et 
al. 1992, Kubosaki, Nishimura-Nasu et al. 2003, Ballerini, Gourdain et al. 2006, Zhang, 
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Steele et al. 2006). This suggests that immunomodulatory functions of PrPC are either 
subtle, or may be relevant only in particular contexts. Expression of PrPC during myeloid 
ontogenesis has been reported by Zhang and colleagues, who found a role for PrP in 
the self-renewal properties of long-term repopulating HSCs (Zhang, Steele et al. 2006). 
In another study, it was shown that the maturation of human CD34+ into CD15+ 
granulocytes is associated to a downregulation of PrPC expression in these cells 
(Dodelet and Cashman 1998). In a similar manner, PrPC levels are downregulated in 
mature neutrophils compared to CD43+ Gr-1+ granulocyte precursors from mouse bone 
marrow (Dodelet and Cashman 1998). On the contrary, maturation of DCs and 
monocytes leads to PrPC upregulation, (Durig, Giese et al. 2000, Burthem, Urban et al. 
2001, Ballerini, Gourdain et al. 2006), even if a causal effect was excluded by 
subsequent experiments on PrP null mice (Ballerini, Gourdain et al. 2006, Linden, 
Martins et al. 2008). PrPC has been proposed to down-regulate phagocytosis by 
macrophages (de Almeida, Chiarini et al. 2005, Wang, Zhao et al. 2014) but also to be 
required for the macrophage invasion by Brucella abortus (Watarai, Kim et al. 2003), 
although this finding has been challenged (Fontes, Alvarez-Martinez et al. 2005). 
Regarding lymphoid ontogenesis, there are contrasting results related to the 
involvement of PrPC. Maturation of T and B lymphocytes in mice has been associated to 
downregulated levels of PrPC while in human and sheep its expression on mature blood 
and lymphoid cells remained high (Politopoulou, Seebach et al. 2000). PrPC expression 
was found to be increased during human NK cell differentiation, particularly in CD56+ 
CD3+ NK T cells (Durig, Giese et al. 2000). Concerning the mature T cell subset, PrPC 
has been found at slightly higher levels in CD8+ compared to CD4+ cells and in 
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CD45RO+ memory compared to CD45RA+ naive T lymphocytes (Durig, Giese et al. 
2000, Politopoulou, Seebach et al. 2000, Li, Liu et al. 2001, Isaacs, Jackson et al. 
2006). Hence, PrPC may be more important in certain types of functionally differentiated 
lymphocytes that operate in particular immune environments. In addition to the 
maturation status of various cell types, PrPC expression also depends on their activation 
status. In this regard, an upregulation of PrP upon activation of T cells, monocytes, and 
DCs has been found (Durig, Giese et al. 2000, Li, Liu et al. 2001, Martínez del Hoyo, 
López-Bravo et al. 2006). Also, treatment with anti-CD3 antibodies or concanavalin A 
(Con A) leads to PrPC upregulation and cell proliferation (Cashman, Loertscher et al. 
1990, Kubosaki, Nishimura-Nasu et al. 2003). Con A-induced proliferation was 
prevented by anti-PrPC antibodies (Cashman, Loertscher et al. 1990). Subsequent 
studies confirmed the upregulation of PrPC following stimulation with multivalent lectins 
(Mabbott, Brown et al. 1997, Li, Liu et al. 2001, Ballerini, Gourdain et al. 2006) and 
showed reduced mitogen-induced proliferation in PrP-null murine splenic lymphocytes 
(Mabbott, Brown et al. 1997, Linden, Martins et al. 2008). Interestingly, following 
stimulation with ConA, which requires the T-cell receptor (TCR) complex, but not after 
stimulation with phorbol ester plus ionomycin, which bypasses the TCR, supernatants of 
transfected PrPC-expressing splenocytes contained higher amounts of both IL-2 and IL-
4, compared to PrP-null splenocytes (Bainbridge and Walker 2005, Linden, Martins et 
al. 2008). Such finding suggests that signalling via elements of the TCR may be 
required to induce changes in PrP expression. Contrary to T lymphocytes, upregulation 
of PrPC was not observed in activated B cells treated with lipopolysaccharide (Kubosaki, 
Nishimura-Nasu et al. 2003). In human T cells PrPC has been found to co-localize 
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and/or co-immunoprecipitate with ganglioside GM3 (Mattei, Garofalo et al. 2002), and to 
a lesser extent GM1 (Hugel, Martinez et al. 2004) and with Fyn, Reggie-1, and 
Lymphocyte-specific tyrosine kinase P56lck (Lck) (Mattei, Garofalo et al. 2004, 
Stuermer, Langhorst et al. 2004). PrPC association with Zeta chain associated protein 
70 kDa (Zap70) was also observed following activation with anti-CD3 and anti-CD28 
(Mattei, Garofalo et al. 2004). However, although PrPC accumulates at sites of T cell-DC 
contact during MHC-peptide stimulation, it does not co-localize with CD3, LFA-1 
(leucocyte function antigen 1), CD43, LAT (linker for activation of T cells) or Thy-1 
(thyroid hormone 1) (Ballerini, Gourdain et al. 2006, Isaacs, Jackson et al. 2006). Thus, 
if PrPC plays a specific role within the immune synapse or if its association to the 
signaling complex involved in T cell activation reflects only a non-specific clustering 
effect is still under debate. 
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1.8 PrP
Sc
 and the immune system 
 
In all TSEs the pathogenic and ultimately lethal effects of prion infection are confined to 
the neuronal tissues of the brain. However, there are many crucial steps occurring in 
lymphatic organs which precede prion neuroinvasion. Three main evidences support the 
involvement of peripheral lymphoid tissues in prion propagation:  
1) Accumulation and early infectivity of lymphoid tissues before clinical symptoms and 
infectivity in the CNS (Hilton, Fathers et al. , van Keulen, Schreuder et al. 1996, 
Andréoletti, Berthon et al. 2000).  
2) Removal of local draining lymphoid tissue blocks subsequent circulation to other 
lymphoid organs and neuroinvasion (Glaysher and Mabbott 2007, Glaysher and 
Mabbott 2007). 
3) Effect of targeted immune impairments on host susceptibility to peripheral inoculation 
(Aguzzi, Heppner et al. 2003). 
In most documented infectious forms of TSEs, prions must transit through the 
lymphoreticular compartment where they spread and multiply without any apparent 
clinical symptoms (Aucouturier and Carnaud 2002). Prions can escape immune 
surveillance, colonize and hijack immune components, replicate in the lymphoreticular 
compartment and finally gain access to the CNS. Of note, severe combined 
immunodeficient (SCID) mice proved to be partially resistant against combined 
intracerebral and intraperitoneal inoculation of BSE cow brain homogenate (Brown, 
Stewart et al. 1997). On the contrary, SCID mice intracerebrally infected with a mouse-
passaged scrapie strain, ME7, produced 100% incidence of the disease (Fraser, Brown 
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et al. 1996). Such results suggest that the peripheral immune system may also give a 
major contribution in interspecies transmission and species-barrier phenomenon. 
Neuroimmunological phenomena also play an important role in the final stages of the 
disease (Aguzzi, Barres et al. 2013). For all these reasons, it is of the utmost 
importance to understand the peripheral mechanisms of prion infection and to identify 
the cell subsets and the genes of the immune systems which are mainly involved in 
prion pathogenesis.  
1.8.1 Prion entry sites and their spread within the host 
 
Entry sites of prions are crucially dependent on the route of infection. Prion inoculation 
via peritoneal, cutaneous, or venous routes typically leads to lymph node and spleen 
invasion first, followed by that of intestine mucosa and spinal cord, and then the brain 
(Aucouturier and Carnaud 2002). As for oral infection, which is the most relevant route 
for acquired prion disease in nature, the first area to be colonized is the gut-associated 
lymphoid tissue (GALT). Studies in natural or experimental scrapie (Maignien, Beringue 
et al. 1999, Sigurdson, Williams et al. 1999, Andréoletti, Berthon et al. 2000, Beekes 
and McBride 2000, Heggebø, Press et al. 2000), in sheep and mice infected with BSE 
(Somerville, Birkett et al. 1997, Maignien, Beringue et al. 1999, Foster, Parnham et al. 
2001) or in deer with CWD (Sigurdson, Williams et al. 1999) indicated a main 
involvement of the ileal Peyer’s patches (PPs). PPs are aggregated lymphoid follicles 
surrounded by a particular epithelium, the follicle-associated epithelium (FAE) (Jung, 
Hugot et al. 2010). Located within the FAE of PPs are microfold cells (M cells), a subset 
of epithelial cells specialized for transepithelial transport of luminal macromolecules and 
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particulate antigens toward the lamina propria, where there are resident antigens 
presenting cells (APCs). M cells have been shown to play a major role in prion uptake, 
since their depletion blocked prion oral infection in C57BL/6 mice infected with ME7 
scrapie prions (Donaldson, Kobayashi et al. 2012). In addition, the rapid accumulation 
of prions in PPs after intra-gastric inoculation and the positive correlation between the 
number of PPs and susceptibility to prion oral infection both argue in favor of FAE of the 
PPs as the most plausible prion entry site (Beekes and McBride 2000, Prinz, Huber et 
al. 2003).  
After crossing the FAE, prions spread — possibly through a cell-mediated mechanism – 
within the lymphatic system and then into the brain. The mesenteric lymph nodes are 
colonized first and the infection proceeds in other secondary lymphoid organs (SLO), 
the sympathetic nervous fibers and myenteric ganglia. Prion accumulation and 
replication within SLO has been found mainly in natural scrapie (Pattison and Millson 
1960), CWD (Sigurdson, Williams et al. 1999), TME (Hadlow, Race et al. 1987) and 
vCJD (Hilton, Fathers et al. 1998). Therefore, prions causing such pathologies are 
indicated as lymphotropic. In some cases, prions may invade the brain directly, without 
spreading in the lymphoid tissues (neurotropic prions) (Mohri, Handa et al. 1987). 
However, no strict distinction can be made between the two forms of the pathology 
since evidence indicates that the extent of lymphotropism of a prion is the result of a 
combination of the prion strain, inoculation route, the host species and the gene 
sequence encoding the prion protein (Aguzzi, Nuvolone et al. 2013). In sharp contrast 
with what happens in the brain, the spreading of prions through the lymphoid tissues is 
not associated with major morphological or functional alterations (Aucouturier and 
39 
 
Carnaud 2002). The finding that prions invade the lymphoreticular system long before 
the CNS opens prospects regarding preclinical diagnosis and prevention of brain 
colonization. Interestingly, direct intracerebral inoculation also results in early infectivity 
of spleen and lymphoid organs (Lawson, Furness et al. 2010). The spleen is one of the 
main organs involved in peripheral prion replication and infectivity (Wadsworth, Joiner et 
al. 2001, Daude 2004). Genetic asplenia or splenectomy prior to, or shortly after, a 
peripheral scrapie challenge significantly extended the survival of mice (Clarke and Haig 
1971, Mabbott, Farquhar et al. 1998). However, the contribution of the spleen in prion 
spread seems to be important only in the first phases of the diseases, since studies of 
splenectomy at different times after peripheral infection showed that survival was not 
extended once the infection had already reached the spinal cord (Kimberlin and Walker 
1989). Fractionation of splenocytes and experiments using sublethal ionizing irradiation 
— which depletes mitotically active haematopoietic cells but not mitotically quiescent 
stromal cells — indicated that most infectivity is present in stromal compartment of the 
spleen rather than hematopoietic one (Lavelle, Sturman et al. 1972, Fraser and 
Farquhar 1987).  
1.8.2 Role of Follicular Dendritic Cells (FDCs) 
 
As FDCs are derived from stromal perivascular precursor cells (Krautler, Kana et al. 
2012) and express high levels of PrPC, they were thought to represent a candidate for 
peripheral prion replication. The FDC are tissue-fixed and non-phagocytic cells localized 
within B cell follicles of lymphoid tissues. It has been found that FDCs are important 
peripheral sites for PrPSc accumulation (Kitamoto, Muramoto et al. 1991) and that 
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FDCs-specific PrPC expression alone is sufficient to sustain prion infection in the spleen 
(McCulloch, Brown et al. 2011). Formation and maintenance of mature FDCs during the 
germinal center response require the presence of B cells expressing membrane-bound 
lymphotoxin-α1/β2 (LTα1β2) (Myers, King et al. 2013). Treatment of mice with soluble 
lymphotoxin-β receptor resulted in the disappearance of mature FDCs from the spleen 
and to the abolishment of splenic prion replication and retarded neuroinvasion after 
intraperitoneal scrapie inoculation (Montrasio, Frigg et al. 2000). In the following years, 
it has emerged that the positioning of FDCs within the spleen controls prion 
neuroinvasion: ablation of the chemokine receptor CXCR5 juxtaposes follicular FDCs to 
major splenic nerves, and accelerates the transfer of intraperitoneally administered 
prions into the spinal cord (Prinz, Heikenwalder et al. 2003). However, ablation of 
TNFR1 (Tumor necrosis factor receptor 1) signaling prevents prion pathogenesis in 
spleen but not in lymph nodes, despite the absence of FDCs (Prinz, Montrasio et al. 
2002). The latter result suggests that, despite the primary role of FDCs, other cell types 
contribute to prion amplification in lymph nodes and probably in the spleen. 
1.8.3 Role of Dendritic Cells (DCs) 
  
The most plausible cells involved in the spread of prion from the FAE are DCs, which 
migrate through the lymphatic system and contribute to prion propagation inside the 
organism (Aguzzi, Nuvolone et al. 2013). DCs are potent APCs which act as a bridge 
between the innate and adaptive immune systems. Once activated, they migrate to the 
lymph nodes where they interact with T and B lymphocytes to initiate an antigen-specific 
immune response or induce tolerance (Banchereau, Briere et al. 2000). In contrast to 
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FDCs, DCs derived from bone-marrow precursors, are migratory cells and have 
phagocytic functions. They are present in those tissues that are in contact with the 
external environment, such as skin (where there are specialized DCs called Langerhans 
cells) or inner layers of intestines, stomach, etc. A subset of DCs is present also in the 
blood. They do not have dendrites and are less mature but still they perform several 
functions such as antigen presentation, chemokine production and INFα secretion. 
Since DCs play a variegate array of functions within the immune system, they can 
interact in diverse ways with prions and contribute in several contrasting manners to 
prion pathogenesis. Some studies revealed that DCs may help in the protection of the 
host against infection by sequestering and destroying the prions (Luhr, Wallin et al. 
2002, Mohan, Hopkins et al. 2005, Rybner-Barnier, Jacquemot et al. 2006). Others 
suggests that prions may exploit DCs as a Trojan horse to enter and spread from the 
infected sites to the lymphoid tissues (Huang, Farquhar et al. 2002, Raymond, 
Aucouturier et al. 2007, Sethi, Kerksiek et al. 2007, Cordier-Dirikoc and Chabry 2008). 
An important role for DCs in peripheral prion spread was highlighted by Raymond and 
colleagues in 2007. They showed that depletion of CD11c+ DCs in vivo impaired prion 
accumulation in GALT and spleen and reduced the susceptibility to orally administered 
prions (Raymond, Aucouturier et al. 2007, Aguzzi, Nuvolone et al. 2013). DCs may also 
be relevant in the subsequent transfer of prions from the periphery to the CNS by 
connecting the immune and peripheral nervous systems (Mabbott and Bradford 2015). 
In a study published by Christelle Langevin and colleagues, it has been shown that 
bone-marrow-derived DCs (BMDCs) are able to transfer PrPSc to cerebellar neurons by 
direct cell–cell contact via tunnelling nanotubes (Langevin, Gousset et al. 2010).  
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1.8.4 Role of B lymphocytes 
 
A 1997 study published by Klein and colleagues revealed an important and unexpected 
role for B cells in prion diseases. Using a panel of immune-deficient mice, the authors 
found that only defects in B cell maturation and activation prevented the development of 
clinical scrapie. Moreover, they found that involvement of B lymphocytes was 
independent from the specificity of their receptors and from the activation of FDCs 
(Klein, Frigg et al. 1997). This discovery was followed by a plethora of follow-up studies. 
Surprisingly, it was found that PrPC expression on B lymphocytes is not required for 
prion neuroinvasion (Klein, Frigg et al. 1998). However, experiments performed on 
chimeric Prnp–/– mice which were reconstituted with wild-type bone marrow or fetal liver 
cells, showed that PrPC expression is required in other cell type to sustain the 
replication of prions in the spleen (Blattler, Brandner et al. 1997, Kaeser, Klein et al. 
2001). Thus, these data indicate that prion replication in the spleen requires a PrPC-
expressing cells of stromal origin that depends, directly or indirectly, on B cells, without 
regard to PrPC expression in the latter (Aguzzi, Nuvolone et al. 2013).  
1.8.5 Role of T lymphocytes 
 
Experiments performed in 1971 by Clark and Haig showed that genetic athymia or 
thymectomy do not extend the survival of mice peripherally inoculated with prions 
(Clarke and Haig 1971). On the other hand, constitutive or acquired lymphocyte 
deficiency was shown to impair prion replication following peripheral, but not 
intracerebral, inoculation of rodent-adapted prions (Kitamoto, Muramoto et al. 1991, 
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Lasmézas, Cesbron et al. 1996, Aguzzi, Nuvolone et al. 2013). Taken together, these 
results indicate that lymphocytes may be important for trafficking prions within lymphoid 
organs but not as major reservoir of infectivity. There is some experimental evidence 
linking T lymphocyte with prion pathology, even though its role in the pathogenic 
process is still far from being elucidated. In a very recent study, it has been found that 
PrPSc is present in the blood from preclinical infected sheep in association with 
monocytes and T lymphocytes (Dassanayake, Madsen-Bouterse et al. 2016). In another 
study, the existence of a CD4+ T cell-mediated immunity against foreign PrPC was 
shown, which may be involved in the species-barrier phenomenon. The authors argue 
that in a natural situation the infectious materials consist of both PrPSc and PrPC, 
therefore they assume that an immune response against PrPC will also affect PrPSc 
(Stoltze, Rezaei et al. 2003). Finally, T lymphocytes may have a role in CNS prion 
pathology, since CD4+ and CD8+ T lymphocytes infiltrates have been found in murine 
and human brains infected with TSE (Lewicki, Tishon et al. 2003). 
1.8.6 Innate immune system in prion disease 
 
The innate immune system is the first defense of the organism against invading 
pathogens. It is evolutionally older with respect to the adaptive immunity and unlike the 
latter it does not maintain immunological memory. Cells of the innate immune system 
recognize a set of generic molecules present on pathogens, collectively known as 
pathogen-associated molecular patterns (PAMPs). Following activation, these immune 
cells release inflammatory mediators, such as cytokines and chemokines, which in turn 
attract and activate other cells of the adaptive and innate immunity. Innate immunity has 
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been shown to play a dual role in TSEs, both abetting and contrasting prion 
pathogenesis (Zabel and Avery 2015). Hereunder some of the components of innate 
immunity as they relate to prion pathology will be discussed. 
1.8.6.1 Complement system 
 
It has been proposed that the first active response to prion infection may be the 
complement system, which is activated during the early phases of TSE pathogenesis 
(Kovacs, Gasque et al. 2004). The complement system is composed of numerous small 
blood proteins that are generally synthesized in the liver but also by tissue-resident 
mononuclear phagocytes (MNPs), epithelial cells and stromal components such as 
FDCs (Bradford and Mabbott 2012). The complement system, including C1q and C3, 
can opsonize PrPSc and aid for its targeting to lymphoid follicles (Mabbott 2004). In 
particular, it has been shown that C1q enhances the uptake of disease-associated PrP 
by classical DCs (Flores-Langarica, Sebti et al. 2009). Regarding a possible role for the 
complement system in CNS prion pathogenesis, at present there is little evidence 
supporting this hypothesis. Absence of C1qa, C2 or C3 did not alter the host response 
to intracerebral inoculation (Klein, Kaeser et al. 2001) and mice lacking C3 and C4 
presented no deficit to prion pathogenesis after aerosol exposure to prions (Haybaeck, 
Heikenwalder et al. 2011).  
1.8.6.2 Macrophages and monocytes 
 
Macrophages, together with dendritic cells, monocytes and Langerhans cells, are part of 
a heterogeneous group of hematopoietic-derived phagocytes known as mononuclear 
45 
 
phagocytes (MNPs). By virtue of their diversity, MNPs may play variegated roles in 
prion pathogenesis. In fact, they may either destroy TSE agents or contribute to their 
spread within the lymphoid system. In literature, a body of evidence exists showing that 
macrophages are able to phagocytize and degrade scrapie and BSE prions (Carp and 
Callahan 1981, Sassa, Inoshima et al. 2010, Sassa, Yamasaki et al. 2010). 
Furthermore, TSE pathogenesis is accelerated in macrophage-depleted mice and 
scrapie accumulation is increased in the spleen (Beringue, Demoy et al. 2000). On the 
other hand, macrophages may be also involved in prion delivery from M cells to 
lymphoid tissues (Takakura, Miyazawa et al. 2011). Finally, with regard to monocytes 
(the precursors of both DCs and macrophages), they may be involved in prion spread 
during the preclinical phase of TSE infection. Indeed, a recent study identified the 
scrapie agent associated to monocytes in blood from naturally affected sheep 
(Dassanayake, Madsen-Bouterse et al. 2016).  
1.8.6.3 Granulocytes 
 
Granulocytes are white blood cells characterized by the presence of granules within the 
cytoplasm, which contain toxic material or inflammatory substances such as 
antimicrobial agents, enzymes, hydrolases, histamine, prostaglandins or nitric oxide. 
Granulocytes are classified as a) basophils, b) eosinophils, c) neutrophils, and, d) mast 
cells. Basophils represent only about 0.5 to 1% of circulating white blood cells. They are 
involved in inflammatory reactions during immune response, as well as in the formation 
of acute and chronic allergic diseases. At present there are no reports linking basophil 
activity and prion disorders. Mast cells are very similar in both appearance and function 
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to the basophils. During the early response to a generic infection they release heparin 
and histamine. Mast cells are able to migrate from blood to brain (Silverman, Sutherland 
et al. 2000) and they do express high levels of PrPC which can be shed upon their 
activation (Haddon, Hughes et al. 2009). Notwithstanding, due to the non-inflammatory 
nature of prion diseases outside the CNS, it is unlikely that mast cells may play a major 
role in peripheral TSE pathology. In some case it has been observed that factors, such 
as C3a and Chemokine (C-C motif) ligand 3 (CCL3), can lead to mast cell activation 
without degranulation (Gilfillan and Tkaczyk 2006), which may occur in TSE infection. In 
the CNS, mast cells exert neuromodulatory functions and their trafficking into the brain 
can be triggered behaviorally (Silver, Silverman et al. 1996). Thus, in the late phases of 
the infection, mast cell could be able to provide the CNS with a copious amount of PrPC 
as substrate for conversion (Bradford and Mabbott 2012). As for eosinophils, they are 
more abundant in the blood with respect to the basophils, representing about 1–6% of 
circulating leukocytes. They do not express PrPC (Barclay, Houston et al. 2002). 
Although amyloid deposits themselves are eosinophilic, there is some evidence to 
indicate the presence of eosinophils within inclusions of both central and peripheral 
amyloid plaques (Iwasaki, Mori et al. 2014). Finally, the neutrophils has been found to 
be inhibited by both native PrP and PrP27-30 (Miragliotta, Fumarulo et al. 1990).  
1.8.6.4 Natural killer (NK) 
 
NK is a type of cytotoxic lymphocyte mainly involved in protection against viral infection 
and tumor formation via the expression of granzyme and perforin. NKs differentiate and 
mature in the bone marrow, lymph nodes, spleen, tonsils and thymus, where they enter 
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into circulation. They are different from the natural killer T cells (NKT), in that they do 
not express TCRs nor CD3 or immunoglobulins. On the contrary, they usually express 
CD16 (FcRIII) and CD56 (also known as NCAM) in humans. Recent research 
highlighted the important functions played by NKs, which go beyond their cytotoxic role 
in innate immunity. Indeed, NKs have been found to be involved in self-tolerance and 
immunological memory. NK cells are typically stimulated via interleukins, 2, 12, 15 and 
18 and chemokine (C-C motif) ligand 5 (CCL5) as well as down-regulation of MHC class 
I molecules following viral infection (Bradford and Mabbott 2012). Overall evidence in 
literature indicates that NKs have little influence on the pathogenesis of prion diseases. 
Indeed, KO mice which did not express perforin did not show any difference in prion 
pathology compared to the wild-type controls (Klein, Frigg et al. 1997). In a recent study 
published by Castro-Seoane and colleagues, high titers of prions were found for the first 
time associated to NK cells (Castro-Seoane, Hummerich et al. 2012). Thus, the fact that 
NKs have not been reported to respond to prion infection could be the consequence of 
immune-escape mechanisms adopted by prions. However, at present there is little 
evidence for such a theory.  
1.8.6.5 Platelet 
 
Platelets, also called thrombocytes, are cells without a nucleus that circulate within the 
blood and form clots in the case of damaged vessels and bleeding (hemostasis). They 
are fragments of cytoplasm derived from the megakaryocytes. Once they recognize an 
injury, they become activated and aggregate. Formation of a platelet plug is associated 
with activation of the coagulation cascade with resultant fibrin deposition and linking. It 
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has been suggested that platelets may have a role in prion spread since some studies 
showed that, within the blood, they express the highest amount of PrPC (Barclay, Hope 
et al. 1999, MacGregor, Drummond et al. 2000). In particular, it has been shown that in 
platelets PrPC is associated to alpha granules, together with proteins such as CD62 
(also known as P-selectin), cluster of differentiation 36 (CD36), transforming growth 
factor β (TGFβ), and insulin-like growth factor 1 (IGF-1) (Starke, Harrison et al. 2005). 
Activated platelets release PrPC initially in small quantities on microvesicles and 
subsequently at higher levels on exosomes. (Perini, Vidal et al. 1996, Robertson, Booth 
et al. 2006). The role of PrPC in platelets, as well the role of platelet-derived exosomes, 
is at present unknown. One hypothesis is that exosomes release is a general 
mechanism for the transport of proteins and, consequently, a vehicle for pathogen 
transmission, including prions, between cells (Fevrier, Vilette et al. 2004, Février, Vilette 
et al. 2005, Porto-Carreiro, Fevrier et al. 2005). Therefore, it has been suggested that 
platelet-derived exosomes could potentially act as an important source of PrPC for prion 
replication (Robertson, Booth et al. 2006). In line with this hypothesis, sheep bioassay 
experiments revealed that platelets, in combination with B lymphocytes, harbor the 
highest level of prion infectivity within blood (Dassanayake, Schneider et al. 2011). 
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1.9 Prion and blood 
 
Recent evidence has emerged that PrPSc can be detected in the blood of humans and 
animals affected by TSEs. Indeed, it is nowadays a matter of fact that prions can be 
transmitted through blood or blood derivatives (Andréoletti, Litaise et al. 2012, Aguzzi, 
Nuvolone et al. 2013). Propagation of prions through blood has been showed by 
Mathiason and colleagues, who found that CWD can be transmitted via blood 
transfusion in deer (Mathiason, Powers et al. 2006). Importantly, it has been shown that 
prion disease can be transmitted by whole blood transfusion during the symptom-free 
phase of experimental BSE infection (Houston, Foster et al. 2000, McCutcheon, Alejo 
Blanco et al. 2011). It seems that not only white cells, but all blood components (red 
cells, plasma and platelets), can transmit prion infection (McCutcheon, Alejo Blanco et 
al. 2011). These reports highlight the importance of finding a preclinical test for vCJD, 
since blood transfusion from asymptomatic vCJD affected patients may represent a risk 
of spread of vCJD infection among the population, especially in UK. At present, the 
prevalence of vCJD infected and asymptomatic individuals in the BSE-exposed 
population remains extremely uncertain (Lacroux, Comoy et al. 2014). According to 
statistical modeling and retrospective studies performed on appendix and tonsil 
samples, the number of vCJD-infected asymptomatic individuals ranges from 900 
(statistical modelling; Clarke et al., 2007) to 3800 (screening of anonymous appendix 
and tonsil tissue archives; Hilton et al., 2004). A more recent study on 32400 appendix 
samples from patients born between 1941 and 1984, indicated a vCJD prevalence even 
higher, equal to 1 over 2000 in this age cohort (Gill, Spencer et al. 2013). Recent 
modeling studies predict a prevalence of vCJD between 84 and 3000 cases in the years 
50 
 
2010 to 2179 (Garske and Ghani 2010, Bishop, Diack et al. 2013). In addition, the 
possibility of silent carrying by vCJD infected individuals was raised by studies on 
human PrP transgenic mouse models which indicated that the BSE agent can colonize 
lymphoid tissues without involving the CNS and causing clinical disease (Béringue, 
Herzog et al. 2012). So far, four cases of vCJD transmission between human patients 
have been identified following blood transfusion from asymptomatic donors who 
subsequently developed vCJD (Llewelyn, Hewitt et al. 2004, Peden, Head et al. 2004, 
Wroe, Pal et al. 2006). Three of them developed clinical disease and the fourth died of 
other causes but was positive for markers of the infection. Case-control studies were 
not able to predict or anticipate these unlucky events (Collins, Law et al. 1999). Many 
attempts have been made to identify prions in blood and to develop a preclinical test for 
TSE detection (Wadsworth, Joiner et al. 2001). Studies in rodent models suggest that 
the levels of infectivity in blood are very low, with buffy coat fractions containing 2 or 10 
intracerebral median lethal dose (LD50) units per mL and 100 LD50 units per mL during 
the asymptomatic and the symptomatic phases of disease, respectively (Brown, Rohwer 
et al. 1998, Edgeworth, Farmer et al. 2011). Whole blood from mice contained as little 
as 10 LD50 units in 1 ml (Cervenakova, Yakovleva et al. 2003). Blood fractions from a 
single vCJD affected patient revealed an infectious titer of 4.45 LD per mL (Douet, Zafar 
et al. 2014). These ranges are several orders of magnitude lower than the sensitivity of 
conventionally used immunoassays. Furthermore, PrPC background in blood is higher 
with respect to any other tissue (Edgeworth, Farmer et al. 2011). Over the past decade 
several approaches have been tested to develop a blood-based diagnostic test for prion 
diseases. Protein Misfolding Cyclic Amplification (PMCA) has been used to detect PrPSc 
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in buffy coat fractions of rodent and sheep blood (Castilla, Saa et al. 2005, Saa, Castilla 
et al. 2006, Thorne and Terry 2008). Human platelets have been used in PMCA 
experiments as substrate for the amplification of PrPSc from variant and sporadic CJD 
brain homogenates (Jones, Peden et al. 2007, Jones, Peden et al. 2009). In 2014 
Lacroux and colleagues identified appropriate conditions and substrates for highly 
efficient and specific in vitro amplification of vCJD/BSE agent using PMCA. With this 
approach they could identify three out of the four tested vCJD affected patients and no 
false positives were observed in 141 healthy controls (Lacroux, Comoy et al. 2014). 
However, as expressed in the paper of Tattum and colleagues, the technical limitations 
associated with PMCA, such as the time scales involved, substrate availability and 
suitability and increasing evidence for the spontaneous generation of protease resistant 
PrP de novo, suggest that PMCA is unlikely to provide the sole technology for a prion 
blood screening assay (Tattum, Jones et al. 2010). Besides PMCA, other approaches 
have been tested, such as magnetic bead-based immunoassay coupled with laser-
induced fluorescence spectrofluorometry (Kim, Wang et al. 2005), sandwich 
conformation-dependent immunoassay with capturing antibody with and without PK 
digestion (Bellon, Seyfert-Brandt et al. 2003, Tattum, Jones et al. 2010) and counting of 
single prion particles bound to a capture-antibody surface (Birkmann, Henke et al. 
2007). Further, optimized solid-state capture matrix coupled with direct 
immunodetection of the surface-bound material was tested by Edgeworth and 
colleagues (Edgeworth, Farmer et al. 2011). Real-time quacking-induced conversion 
(RT-QuiC) assay of cerebrospinal fluid and was used to distinguish with high sensitivity 
CJD from non-CJD condition (Orru, Groveman et al. 2015). Miele and colleagues used 
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differential display analysis of cDNAs to identify transcripts that were differentially 
expressed during the course of prion diseases (Miele, Manson et al. 2001). With this 
unbiased 'transcriptomics' approach they could identify a downregulated transcript 
coding for erythroid differentiation-related factor (EDRF), a protein mainly found in 
erythroid precursors—a cell lineage that nobody would have suspected to be associated 
with prions. Such discovery opened the doors to a genomic approach to prion 
diagnostic. 
 
2. Aims 
The aim of this study was to identify common transcriptome changes in whole blood 
from atypical H- and L- type-infected animals prior and after the onset of the clinical 
signs. This approach would allow the identification of candidate genes that could be 
further investigated as biomarkers of the disease. In addition, our study could contribute 
to shed light on the peripheral mechanisms of prion infection.  
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3. Results 
 
3.1 Preparation and selection of samples for microarray 
analysis.  
 
To investigate if gene expression alterations were present in blood from atypical BSE-
infected cattle (clinical and preclinical), we performed microarray experiments using 
Affymetrix GeneChip® Bovine Genome Array. Frozen blood samples collected from 
preclinical and clinical infected cattle (from Konold’s study group: Konold et al 2012) 
were sent in dry ice from the Animal Health and Veterinary Laboratories Agency 
(AHVLA, UK) to the Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle 
d'Aosta (IZSPLV, Turin, Italy), where RNA isolation was performed in a BSL3 facility. A 
first trial set of RNA samples was purified and eluted in 100 µL of RNase free water. 
These samples were frozen and sent to SISSA (Trieste, Italy) for subsequent analysis. 
Their concentration and quality was assessed by capillary electrophoresis. We 
observed quite a low RNA concentration for the majority of the samples as well as a low 
RNA Integrity Number (RIN) value for many of them. These samples did not satisfy the 
minimal requirements for proceeding to the microarray analysis. Therefore, we tried to 
improve the extraction protocol for RNA isolation and we obtained new purified samples 
from our collaborators at IZSTO. Such samples were eluted in 50 µL of RNase free 
water instead of 100 µL in order to increase the overall concentration. Non-Stick RNase-
free Microfuge Tubes (Ambion) were used to collect the samples. Furthermore, an 
additional step of DNase I treatment was included in the RNA extraction protocol to 
reduce DNA contamination and increase the overall RNA quality. We found that the 
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integrity of this new sample set was considerably improved. However, their 
concentrations were still very low (a minimum concentration of 33 ng/uL is required for 
the microarray protocol). At this point, we decided to concentrate the samples by using 
a Labconco CentriVap concentrator. Following this procedure the concentration of the 
samples increased significantly and the quality was maintained satisfactory for the 
majority of them (Table 1). 
Table 1. List of RNA samples isolated from blood of infected and control animals.  
Sample 
name 
Sample type Concentration 
(ng/µL) 
Concentration after 
Centrivap protocol 
(ng/µL) 
RIN Value after 
Centrivap 
protocol 
P1 Preclinical H type BSE 15 77.2 5.5 
P2 Preclinical H type BSE 21 125.4 6.8 
cP3 Control (preclinical) 18 78 6.6 
P4 Preclinical L type BSE 12 146.8 6.5 
P5 Preclinical L type BSE 19 56 5.5 
S1 Clinical H type BSE 19 111.4 7.1 
S2 Clinical H type BSE 15 146.6 7.9 
S3 Clinical L type BSE 38 237.2 N/A 
S4 Clinical L type BSE 7 48.4 N/A 
cS5 Control (clinical) 13 40.0 7.8 
cP6 Control (preclinical) 10 51.9 6.6 
P7 Preclinica H type BSE 16 98.8 7.2 
P8 Preclinica H type BSE 8 58.4 6.7 
P9 Preclinica L type BSE 12 69.4 2.2 
P10 Preclinica L type BSE 20 116.0 6.4 
cS6 Control (clinical) 10 63 8.4 
S7 Clinical H type BSE 15 86.5 7.5 
S8 Clinical H type BSE 15 108.2 6.8 
S9 Clinical L type BSE 17 100.5 8.7 
S10 Clinical L type BSE 15 86.4 7.8 
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Since the sample size of controls was quite limited and much smaller with respect to 
that of the infected animals (only four control samples vs sixteen infected samples) we 
decided to include additional sex-matched negative controls in our study. These cattle 
were aged from 12 to 37 months and derived from a different herd compared to the 
Konold’s study groups. Again for these samples the RNA concentration was quite low, 
and therefore we proceeded with the concentration at Centrivap. After this procedure 
the final amount of RNA per volume was satisfactory for the majority of them and the 
high integrity was maintained (Table 2). 
Table 2. Additional negative control samples. 
Sample 
name 
Sample 
type 
Concentration 
(ng/µL) 
Concentration after 
Centrivap protocol 
(ng/µL) 
RIN Value after 
Centrivap protocol 
c1 Control 11 35 7.4 
c2 Control 23 65 7.1 
c3 Control 29 88,9 6.7 
c4 Control 19 59.1 7.6 
c5 Control 11 49.4 7.2 
c6 Control 14 27.7 7.6 
c7 Control 13 21.6 7.6 
c8 Control 15 23.9 7.4 
c9 Control 27 83.8 7.2 
 
In order to have an equal sample size for preclinical, clinical and control population, we 
selected four control samples to be included in the microarray analysis. Such samples 
were selected on the basis of their concentration and quality (RIN value) and are 
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highlighted in bold in Table 2. Thus, we had 8 preclinical, 8 clinical and 8 control 
samples (4 from the Konold’s study and 4 from a different herd) which were subjected to 
the microarray hybridization. This analysis had to be performed in 3 different moments 
due to the capacity of the microarray chip scanner. Therefore, we divided our population 
in three sample sets which were subjected to the microarray hybridization and staining 
protocol in different moments. Each sample set was composed of a balanced number of 
control, preclinical and clinical samples in order to reduce technical biases due to inter 
run variability. The sample sets are indicated in Table 3. 
Table 3. Sample sets which were subjected to the microarray hybridization and staining 
protocol in different moments. 
 Preclinical sample Clinical sample Control sample 
First 
sample set 
P2 S2 cP3 
 
P7 S7 cS5 
 
P8 S8 c3 
Second 
sample set 
P4 S3 c9 
 
P5 S4 c5 
 
P9 S9 c2 
Third 
sample set 
P10 S10 cS6 
 
P1 S1 cP6 
 
Microarray hybridization for the first and third sample set were repeated twice since 
some technical problems occurred. The first sample set (composed of sample P2, P7, 
P8, S2, S7, S8, cP3, cS5 and c3) was characterized by low signal intensities compared 
to the rest of the arrays (Figure 1A). Probably, a problem during the staining step of the 
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microarray protocol occurred. Therefore, we repeated the staining for such samples and 
could obtain intensity signals comparable to the rest of the arrays (Figure 1B). 
A 
      
B 
      
      
Figure 1. Raw intensity boxplots for each array. In the first analysis the intensity of the arrays 
corresponding to the first sample set was quite low compared to the rest of the chips (A). After 
repeating the staining of the first sample set the signal intensities were more homogeneous 
among all the arrays (B).  
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Concerning the third sample set, we observed a very low amount of aRNA following the 
amplification step of the microarray protocol. After some tests it was found that the 
problem was the eluent used during the experiments. By changing the eluent stock the 
aRNA could be rescued in high concentration. Once we solved these technical issues, 
further microarray quality control (MAQC) was performed to assess the quality of each 
array. Relative log expression (RLE) and normalized unscaled standard error (NUSE) 
plots were examined in order to avoid procedural failures and the presence of degraded 
RNA samples. On the RLE plot, arrays with lower quality will have boxes that are 
centred higher and/or have a larger spread than the other good quality arrays from the 
same experiment. As shown in Figure 2A, we found that the array corresponding to the 
control sample cS5 was centred higher and had a larger spread compared to the rest of 
the arrays. In line with RLE plot, also the NUSE plot indicated a low quality for this 
sample. NUSE represents normalized standard error (SE) estimates from the probe 
level model (PLM) fit. The SE estimates are normalized such that for each probe set, 
the median standard error across all arrays is equal to 1. Typically, boxes centred 
above 1.1 represent arrays that have quality problems. Indeed, sample cS5 was centred 
above 1.1 and had a much larger spread compared to the rest of the samples (Figure 
2B).  
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A   
                                                                                                                                                                                                                                                                                                                                                 
B     
       
 
Figure 2. Post hybridization quality assessment. Relative log expression (RLE) (A) and 
normalized unscaled standard error (NUSE) (B) plots are used to check for technical problems 
and to spot outlier samples after GCRMA normalization. One outlier was easily identified by 
post hybridization quality assessment (black arrow in panel A and B, control sample cS5). 
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Due to these quality problems, we decided to exclude the control sample cS5. However, 
in order to see in which degrees the results could be affected by the removal of such 
sample, we carried out two preliminary statistical analyses, one including and one 
excluding the sample. We could find 141 differentially expressed probes in the first 
analysis (all infected samples vs all control samples) and 144 in the second analysis (all 
infected samples vs all control samples excluding sample cS5). 86 genes were in 
common between the two analyses. To be the most conservative as possible, for the 
final selection of DEGs to be validated by RT-qPCR, in addition to the p value and the 
fold change, we took into account also this preliminary comparison (thus favouring 
those genes which remained significant after the removal of sample cS5). Finally, we 
could improve our data by substituting sample P9, which displayed the lowest RIN value 
(2.2 in Table 1), with a new high quality RNA batch (named as sample EP9) isolated 
from the same animal (RIN value for sample EP9 was equal to 9.2). Summarizing, after 
removal of one outlier control sample (cS5) and substitution of one low-quality 
preclinical sample (P9->EP9), the final microarray statistical analyses were performed 
using 23 samples: 8 preclinical (P1, P2, P4, P5, P7, P8, EP9 and P10), 8 clinical (S1, 
S2, S3, S4, S7, S8, S9 and S10), and 7 control samples (c2, c3, cP3, c5, cP6, cS6 and 
c9). The final statistical analyses, showed in detail in the next paragraph, were four: 
infected (H- and L-type) versus control (IvsCtrl), preclinical versus control (PvsCtrl), 
clinical versus control (CvsCtrl) and clinical versus preclinical (CvsP) analysis.  
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3.2 Identification of differentially expressed genes (DEGs) in 
the blood of atypical BSE-infected cattle by microarray 
analysis. 
 
Statistical analysis was performed on microarray results using the oneChannelGUI 
Bioconductor package (Sanges, Cordero et al. 2007). The raw microarray data were 
deposited in the Gene Expression Omnibus (GEO) repository and assigned the 
accession number GSE69048 (see section: Availability of supporting data). 
Since the goal of this project was to identify a common pattern of DEGs in atypical BSE 
infection, we defined the 4 H- and the 4 L- type inoculated-cattle as one single group of 
8 animals named as atypical infected cattle. This approach allowed us to increase the 
sample size and obtain more reliable results. Indeed, in a preliminary analysis 
comparing the 4 H-type and the 4 L-type infected animals we found a limited number of 
DEGs: only 15 had a p value lower than 0.01 and only 16 showed a fold change higher 
than 3 (see Table 4).  
Table 4. List of DEGs found in HvsL statistical comparison. 
Probe ID Gene symbol Gene name P value Fold Change 
Bt.16070.3.A1_
at 
LOC786352 apolipoprotein L, 1-like 4.36E-06 -7.064 
Bt.8382.2.S1_at RHOB 
ras homolog gene family, 
member B 
6.07E-05 2.285  
Bt.28461.2.S1_
a_at 
INSR insulin receptor 7.58E-05 -6.156 
Bt.7220.1.S1_at BLA-DQB MHC class II antigen 1.82E-04 -112.648 
Bt.9173.1.A1_at NBEAL2 neurobeachin-like 2 2.57E-04 2.410 
Bt.215.1.S1_at HLA-DQA1 
major histocompatibility complex, 
class II, DQ alpha 5 
4.45E-04 -170.841 
Bt.20925.1.S1_
at 
BOLA-DQB 
major histocompatibility complex, 
class II, DQ beta 
6.49E-04 -62.998 
Bt.28461.1.S1_
a_at 
INSR insulin receptor 8.66E-04 -3.242 
Bt.9605.1.S1_at MS4A8B membrane-spanning 4-domains, 1.35E-03 2.461 
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subfamily A, member 8B 
Bt.23226.1.S1_
at 
ACADSB 
acyl-CoA dehydrogenase, 
short/branched chain 
1.45E-03 -2.300 
Bt.27760.1.S1_
at 
BoLA /// BOLA-
A 
major histocompatibility complex, 
class I, A /// major 
histocompatibility complex, class 
I, A 
1.57E-03 -4.832 
Bt.22734.1.A1_
at 
ENPP4 
ectonucleotide 
pyrophosphatase/phosphodieste
rase 4 (putative) 
2.03E-03 3.447 
Bt.16070.2.S1_
at 
LOC786352 apolipoprotein L, 1-like 2.76E-03 -3.006 
Bt.29692.1.S1_
at 
TRD@ T-cell receptor delta chain 3.42E-03 -6.658 
Bt.6147.1.S1_a
_at 
METTL12 methyltransferase like 12 4.53E-03 -2.034 
Bt.22785.1.S1_
at 
CEBPB 
CCAAT/enhancer binding protein 
(C/EBP), beta 
6.56E-03 2.175 
Bt.27261.2.S1_
at 
LOC100847574 
multidrug resistance-associated 
protein 4-like 
0.010996  -4.342 
Bt.1658.1.S1_at DUSP1 dual specificity phosphatase 1 1.30E-02 2.072 
Bt.24441.1.S1_
at 
LOC100336589 
leukocyte immunoglobulin-like 
receptor, subfamily A (with TM 
domain), member 6-like 
1.36E-02 3.580 
Bt.11525.1.S1_
a_at 
RBPMS 
RNA binding protein with 
multiple splicing 
1.64E-02 2.145 
Bt.5230.1.S1_at ID3 
inhibitor of DNA binding 3, 
dominant negative helix-loop-
helix protein 
1.64E-02 -2.674 
Bt.4762.1.S1_at BOLA-NC1 
non-classical MHC class I 
antigen 
1.65E-02 -2.403 
Bt.1736.1.A1_at SOCS1 
suppressor of cytokine signaling 
1 
1.67E-02 2.327 
Bt.29403.1.S1_
at 
TFF2 trefoil factor 2 1.69E-02 -5.802 
Bt.155.1.S1_at IL8 interleukin 8 1.70E-02 2.201 
Bt.4609.1.S1_at LOC100847474 uncharacterized LOC100847474 1.76E-02 -2.893 
Bt.24154.1.A1_
at 
TFDP2 
transcription factor Dp-2 (E2F 
dimerization partner 2) 
1.78E-02 2.316 
Bt.18566.1.A1_
at 
LOC539805 uncharacterized LOC539805 1.84E-02 -2.014 
Bt.21546.1.S1_
at 
LOC516579 
probable phospholipid-
transporting ATPase IIA-like 
1.93E-02 2.524 
Bt.27854.1.S1_
at 
NFIL3 
nuclear factor, interleukin 3 
regulated 
1.98E-02 2.064 
Bt.5847.1.S1_at GPD2 
glycerol-3-phosphate 
dehydrogenase 2 (mitochondrial) 
2.01E-02 -4.420 
Bt.27973.1.S1_
at 
SLCO3A1 
solute carrier organic anion 
transporter family, member 3A1 
2.09E-02 2.151 
Bt.29715.1.S1_
at 
PTPRC 
protein tyrosine phosphatase, 
receptor type, C 
2.15E-02 -2.045 
Bt.22143.1.A1_
at 
SYT4 synaptotagmin IV 2.18E-02 2.088 
Bt.19937.2.S1_
at 
LOC532189 carboxypeptidase D-like 2.25E-02 2.280 
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Bt.7145.1.S1_at 
GZMB /// 
LOC100125946 
granzyme B (granzyme 2, 
cytotoxic T-lymphocyte-
associated serine esterase 1) /// 
uncharacterized LOC100125946 
2.50E-02 -2.850 
Bt.16350.2.A1_
s_at 
GBP5 guanylate binding protein 5 2.51E-02 -2.468 
Bt.8724.1.S1_at LOC100299281 
quinone oxidoreductase-like 
protein 2-like 
2.68E-02 2.035 
Bt.2749.1.S1_at CDKN1A 
cyclin-dependent kinase inhibitor 
1A (p21, Cip1) 
2.73E-02 2.833 
Bt.25269.1.S1_
at 
GCA 
grancalcin, EF-hand calcium 
binding protein 
2.78E-02 2.879 
Bt.21724.2.S1_
a_at 
FDFT1 
farnesyl-diphosphate 
farnesyltransferase 1 
2.99E-02 -2.370 
Bt.13628.1.S1_
at 
TGM3 
transglutaminase 3 (E 
polypeptide, protein-glutamine-
gamma-glutamyltransferase) 
3.02E-02 2.126 
Bt.23399.1.S1_
at 
PKM pyruvate kinase, muscle 3.04E-02 2.058 
Bt.19308.1.S1_
at 
BACH2 
BTB and CNC homology 1, basic 
leucine zipper transcription factor 
2 
3.07E-02 -2.451 
Bt.28027.1.S1_
at 
LOC785752 /// 
LOC789653 
uncharacterized LOC785752 /// 
TRD@ protein-like 
3.15E-02 -4.060 
Bt.49.1.S1_at CD40LG CD40 ligand 3.16E-02 -2.364 
Bt.21225.1.S1_
at 
EYA3 
eyes absent homolog 3 
(Drosophila) 
3.51E-02 2.183 
Bt.21986.1.A1_
a_at 
USP7 
ubiquitin specific peptidase 7 
(herpes virus-associated) 
3.86E-02 -2.315 
Bt.27261.1.S1_
at 
LOC100337108 uncharacterized LOC100337108 3.98E-02 -10.885 
Bt.28732.1.S1_
at 
TRD@ T-cell receptor delta chain 4.04E-02 -2.147 
Bt.5075.1.S1_at SPINT2 
serine peptidase inhibitor, Kunitz 
type, 2 
4.30E-02 -2.093 
Bt.1847.1.S1_at LOC789748 
Sialic acid-binding Ig-like lectin 
14-like 
4.59E-02 2.047 
Bt.29747.1.S1_
at 
LOC100851578 uncharacterized LOC100851578 4.77E-02 -2.484 
 
The final microarray analysis consisted in 4 statistical comparisons: infected (preclinical 
and clinical) versus control (IvsCtrl), preclinical versus control (PvsCtrl), clinical versus 
control (CvsCtrl) and clinical versus preclinical (CvsP). Statistical comparison between 
the infected animals and the control group (IvsCtrl) revealed a total of 101 differentially 
regulated probe sets (p value lower than 0.05 and changes in expression higher than 2-
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fold) as shown in Table 5. Gene annotation revealed that some of these probe sets 
encoded for the same gene and that 93 of the identified DEGs had a known function.  
Table 5. Differentially expressed genes found in infected animals versus control 
group (IvsCtrl) by microarray analysisa. 
Probe ID Gene symbol Gene name P value Fold 
Change 
Bt.6653.2.A1_at ALKBH4 alkB, alkylation repair homolog 4 (E. coli) 1.35E-07 -2.317 
Bt.8586.1.S1_at LOC512150 myeloid-associated differentiation marker-like 4.17E-05 4.192 
Bt.21996.1.S1_at IGHE Immunoglobulin heavy constant epsilon 4.77E-05 -5.104 
Bt.16101.1.S1_s_at GNLY /// 
LOC100300483 
granulysin /// antimicrobial peptide NK-lysin-
like 
5.70E-05 -4.177 
Bt.28383.1.S1_at GNLY granulysin 8.98E-05 -4.834 
Bt.9265.2.S1_at BATF basic leucine zipper transcription factor, ATF-
like 
1.12E-04 -2.571 
Bt.14153.1.S1_at NEB nebulin 1.45E-04 -4.896 
Bt.16101.1.S1_at GNLY granulysin 2.12E-04 -4.810 
Bt.12986.1.S1_at MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 2.35E-04 -2.722 
Bt.9265.1.A1_at BATF basic leucine zipper transcription factor, ATF-
like 
2.36E-04 -2.553 
Bt.23123.1.S1_at BHLHE40 basic helix-loop-helix family, member e40 5.75E-04 -2.369 
Bt.26326.1.A1_at MTBP Mdm2, transformed 3T3 cell double minute 2, 
p53 binding protein (mouse) binding protein, 
104kDa 
6.23E-04 2.785 
Bt.22526.1.S1_at HSPB8 heat shock 22kDa protein 8 8.58E-04 -2.393 
Bt.16916.3.S1_at KLF11 Kruppel-like factor 11 9.29E-04 4.456 
Bt.24923.2.S1_a_at SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 1.06E-03 -3.342 
Bt.8804.1.S1_at NELL2 NEL-like 2 (chicken) 1.17E-03 -2.350 
Bt.28654.1.S1_at LOC100850906 
/// USP42 
ubiquitin carboxyl-terminal hydrolase 42-like 
/// ubiquitin specific peptidase 42 
1.32E-03 3.550 
Bt.18321.1.A1_at GNB4 guanine nucleotide binding protein (G 
protein), beta polypeptide 4 
1.34E-03 8.268 
Bt.24630.2.S1_at 41527 septin 10 1.37E-03 -3.330 
Bt.21975.1.S1_at PRF1 perforin 1 (pore forming protein) 1.55E-03 -2.006 
Bt.20330.1.S1_at PRSS23 protease, serine, 23 1.70E-03 -3.423 
Bt.24929.1.A1_at RG9MTD3 RNA (guanine-9-) methyltransferase domain 1.90E-03 2.421 
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containing 3 
Bt.6968.1.S1_at IPCEF1 Interaction protein for cytohesin exchange 
factors 1 
1.96E-03 2.425 
Bt.9675.1.S1_at LOC100847724 extracellular peptidase inhibitor-like 2.12E-03 -3.528 
Bt.21979.1.S1_at CXCR6 chemokine (C-X-C motif) receptor 6 2.16E-03 -2.209 
Bt.9504.1.A1_at CCL4 chemokine (C-C motif) ligand 4 2.85E-03 -2.650 
Bt.28040.1.S1_at LOC781494 myeloid-associated differentiation marker-like 3.00E-03 -3.596 
Bt.23505.1.S1_at PDK4 pyruvate dehydrogenase kinase, isozyme 4 3.18E-03 3.186 
Bt.24236.1.S1_at DLC1 deleted in liver cancer 1 3.56E-03 2.297 
Bt.26636.1.S1_at NKG7 natural killer cell group 7 sequence 3.81E-03 -2.169 
Bt.6147.1.S1_a_at METTL12 methyltransferase like 12 4.46E-03 -2.151 
Bt.49.1.S1_at CD40LG CD40 ligand 4.52E-03 -3.237 
Bt.26259.1.A1_at ZNF462 zinc finger protein 462 4.81E-03 3.969 
Bt.15915.1.S1_at LRRC70 leucine rich repeat containing 70 5.10E-03 2.154 
Bt.17280.1.S1_at PLEKHH1 pleckstrin homology domain-containing family 
H member 1-like 
5.12E-03 2.357 
Bt.29009.1.A1_at RYR3 ryanodine receptor 3 5.25E-03 -5.464 
Bt.2129.1.S1_at LOC100850064 versican core protein-like 5.94E-03 2.002 
Bt.22415.2.A1_at LOC512863 sialic acid-binding Ig-like lectin 14-like 6.31E-03 2.231 
Bt.19308.1.S1_at BACH2 BTB and CNC homology 1, basic leucine 
zipper transcription factor 2 
6.60E-03 3.175 
Bt.16861.1.A1_at LOC515128 major facilitator superfamily domain-
containing protein 4-like 
6.68E-03 2.319 
Bt.22301.1.S1_at ATP6V0A4 ATPase, H+ transporting, lysosomal V0 
subunit a4 
6.82E-03 -2.307 
Bt.15705.1.S1_at DSTN destrin (actin depolymerizing factor) 6.91E-03 2.216 
Bt.28637.1.S1_at LOC100848843 myeloid-associated differentiation marker-like 7.71E-03 2.740 
Bt.24983.1.A1_at DYNC2H1 dynein, cytoplasmic 2, heavy chain 1 8.14E-03 -2.085 
Bt.24543.1.A1_at KCTD1 potassium channel tetramerisation domain 
containing 1 
1.02E-02 2.673 
Bt.16916.1.S1_at KLF11 Kruppel-like factor 11 1.02E-02 2.110 
Bt.11259.1.S1_at IFI27 putative ISG12(a) protein 1.09E-02 3.109 
Bt.17081.2.S1_at LMO2 LIM domain only 2 (rhombotin-like 1) 1.16E-02 -2.375 
Bt.22214.1.S1_at CD180 CD180 molecule 1.16E-02 -2.044 
Bt.7145.1.S1_at GZMB /// 
LOC100125946 
granzyme B (granzyme 2, cytotoxic T-
lymphocyte-associated serine esterase 1) /// 
uncharacterized LOC100125946 
1.50E-02 -3.156 
Bt.20540.1.S1_at CD79B CD79b molecule, immunoglobulin-associated 
beta 
1.51E-02 -3.586 
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Bt.20257.2.S1_at BCNT2 Bucentaur-2 1.59E-02 -2.289 
Bt.155.1.S1_at IL8 interleukin 8 1.60E-02 2.250 
Bt.24112.1.A1_at CXHXorf57 chromosome X open reading frame, human 
CXorf57 
1.60E-02 -2.760 
Bt.18253.1.A1_at KIAA1324L KIAA1324-like ortholog 1.61E-02 2.360 
Bt.27043.2.S1_at FCER1A Fc fragment of IgE, high affinity I, receptor 
for; alpha polypeptide 
1.62E-02 -2.063 
Bt.13469.1.S1_at SDSL serine dehydratase-like 1.63E-02 -2.506 
Bt.9262.1.A1_at SPIB Spi-B transcription factor (Spi-1/PU.1 related) 1.67E-02 -3.493 
Bt.9974.1.S1_at CCL3 chemokine (C-C motif) ligand 3 1.71E-02 -2.110 
Bt.19014.1.A1_at NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa (NADH-coenzyme Q 
reductase) 
1.74E-02 4.152 
Bt.2899.1.S2_at FOS FBJ murine osteosarcoma viral oncogene 
homolog 
1.77E-02 2.487 
Bt.6438.1.A1_at TGFB2 transforming growth factor, beta 2 1.91E-02 3.437 
Bt.3352.1.S1_at ASIP agouti signaling protein 1.97E-02 -2.093 
Bt.9163.2.S1_at P2RY10 purinergic receptor P2Y, G-protein coupled, 
10 
1.97E-02 -2.047 
Bt.27760.1.S1_at BoLA /// BOLA-A major histocompatibility complex, class I, A /// 
major histocompatibility complex, class I, A 
2.07E-02 -3.409 
Bt.3805.1.S1_at BOLA-N /// 
JSP.1 /// 
LOC100125916 
MHC class I antigen /// MHC Class I JSP.1 /// 
uncharacterized protein 100125016 2.13E-02 3.897 
Bt.17019.1.A1_at FOXP1 Forkhead box P1 2.14E-02 2.003 
Bt.20640.1.A1_at C22H3orf64 chromosome 22 open reading frame, human 
C3orf64 
2.18E-02 2.039 
Bt.411.1.S1_at NRG1 neuregulin 1 2.19E-02 2.758 
Bt.11847.1.A1_at XIST X (inactive)-specific transcript 2.30E-02 -21.298 
Bt.24923.1.S1_at SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 2.36E-02 -3.251 
Bt.13367.1.A1_at XIST X (inactive)-specific transcript 2.42E-02 -34.673 
Bt.29820.1.S1_s_at BOLA MHC class I heavy chain 2.49E-02 -6.083 
Bt.23911.1.A1_at XIST X (inactive)-specific transcript 2.52E-02 -29.733 
Bt.22139.1.S1_at COBLL1 COBL-like 1 2.64E-02 -2.766 
Bt.22854.1.S1_at CA2 carbonic anhydrase II 2.68E-02 -2.336 
Bt.13330.1.S1_at PDK4 pyruvate dehydrogenase kinase, isozyme 4 2.82E-02 2.400 
Bt.16070.2.S1_at LOC786352 apolipoprotein L, 1-like 2.89E-02 -2.314 
Bt.17473.2.S1_at RPE ribulose-5-phosphate-3-epimerase 3.04E-02 2.209 
Bt.16966.1.S1_at CXCL10 chemokine (C-X-C motif) ligand 10 3.05E-02 -3.066 
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Bt.23172.1.S1_at BAX BCL2-associated X protein 3.07E-02 -2.288 
Bt.4609.1.S1_at LOC100847474 uncharacterized LOC100847474 3.18E-02 -2.619 
Bt.20687.1.A1_at C5H12orf35 chromosome 5 open reading frame, human 
C12orf35 
3.24E-02 2.091 
Bt.3651.2.A1_at C15H11orf96 chromosome 15 open reading frame, human 
C11orf96 
3.52E-02 2.093 
Bt.5408.1.A1_at UCHL1 ubiquitin carboxyl-terminal esterase L1 
(ubiquitin thiolesterase) 
3.52E-02 2.097 
Bt.7015.1.S1_at EED embryonic ectoderm development 3.65E-02 -2.089 
Bt.14010.1.S1_at PTGR1 prostaglandin reductase 1 3.67E-02 -2.194 
Bt.2899.1.S1_at FOS FBJ murine osteosarcoma viral oncogene 
homolog 
3.78E-02 2.466 
Bt.1075.1.A1_at ZNF24 zinc finger protein 24 3.83E-02 2.708 
Bt.20494.1.S1_at RYBP RING1 and YY1 binding protein 3.86E-02 2.158 
Bt.27261.2.S1_at LOC100847574 multidrug resistance-associated protein 4-like 4.03E-02 3.296 
Bt.23094.1.A1_at AKR1C4 /// 
LOC506594 
aldo-keto reductase family 1, member C4 
(chlordecone reductase; 3-alpha 
hydroxysteroid dehydrogenase, type I; 
dihydrodiol dehydrogenase 4) /// 
prostaglandin F synthase 1-like 
4.11E-02 -2.137 
Bt.20540.3.A1_at CD79B CD79b molecule, immunoglobulin-associated 
beta 
4.23E-02 -2.063 
Bt.24372.1.S1_at ZRSR2Y zinc finger (CCCH type), RNA-binding motif 
and serine/arginine rich 2 
4.27E-02 3.787 
Bt.7122.1.S1_at HELZ helicase with zinc finger 4.36E-02 2.564 
Bt.213.1.S1_at CD163L1 CD163 molecule-like 1 4.73E-02 2.500 
Bt.20216.2.S1_at RPIA ribose 5-phosphate isomerase A 4.83E-02 -2.068 
Bt.27759.2.S1_at IDO1 indoleamine 2,3-dioxygenase 1 4.85E-02 -3.729 
Bt.29815.1.S1_x_at BOLA MHC class I heavy chain 4.85E-02 -3.122 
Bt.15705.1.S2_at DSTN destrin (actin depolymerizing factor) 4.86E-02 2.055 
Bt.16933.2.A1_at LOC100298891 aTP-binding cassette, sub-family C 
(CFTR/MRP), member 4-like 
4.91E-02 2.748 
 
Enrichment analysis revealed the involvement of many pathways and functional 
categories, including chemotaxis, inflammatory response and antigen presentation via 
MHC, which may be involved in peripheral prion pathogenesis. The most relevant 
functional groups are reported in Table 6.  
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Table 6. Functional classification of differentially expressed genes in blood of 
infected cattle versus control groupa.  
Pathway Probe name 
Gene 
symbol 
Gene name P value 
Fold 
Enrichment 
Autoimmun
e thyroid 
disease 
BT.21975.1.S1_
AT 
PRF1 perforin 1 (pore 
forming protein) 
1.01E-04 19.14728
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BT.29815.1.S1_
X_AT 
BOLA MHC class I heavy 
chain 
  
 
BT.29820.1.S1_
S_AT 
BOLA MHC class I heavy 
chain 
  
 
BT.3805.1.S1_
AT 
BOLA-N /// 
JSP.1 /// 
LOC1001259
16 
MHC class I antigen 
/// MHC Class I 
JSP.1 /// 
uncharacterized 
protein 100125016 
  
 BT.49.1.S1_AT CD40LG CD40 ligand   
 
BT.7145.1.S1_
AT 
GZMB /// 
LOC1001259
46 
granzyme B 
(granzyme 2, 
cytotoxic T-
lymphocyte-
associated serine 
esterase 1) /// 
uncharacterized 
LOC100125946 
  
Extracellula
r region 
BT.155.1.S1_A
T 
IL8 interleukin 8 2.22E-04 3.036995
516 
 
BT.16070.2.S1_
AT 
LOC786352 apolipoprotein L, 1-
like 
  
 
BT.16966.1.S1_
AT 
CXCL10 chemokine (C-X-C 
motif) ligand 10 
  
 
BT.20330.1.S1_
AT 
PRSS23 protease, serine, 23   
 
BT.20640.1.A1_
AT 
C22H3orf64 chromosome 22 
open reading frame, 
human C3orf64 
  
 
BT.2129.1.S1_
AT 
LOC1008500
64 
versican core 
protein-like 
  
 BT.213.1.S1_A CD163L1 CD163 molecule-like   
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T 1 
 
BT.29009.1.A1_
AT 
RYR3 ryanodine receptor 3   
 BT.49.1.S1_AT CD40LG CD40 ligand   
 
BT.6438.1.A1_
AT 
TGFB2 transforming growth 
factor, beta 2 
  
 
BT.8804.1.S1_
AT 
NELL2 NEL-like 2 (chicken)   
 
BT.9504.1.A1_
AT 
CCL4 chemokine (C-C 
motif) ligand 4 
  
 
BT.9974.1.S1_
AT 
CCL3 chemokine (C-C 
motif) ligand 3 
  
 
BT.3352.1.S1_
AT 
ASIP agouti signaling 
protein 
  
Immune 
response 
BT.155.1.S1_A
T 
IL8 interleukin 8 4.91E-04 5.451442
755 
 
BT.16966.1.S1_
AT 
CXCL10 chemokine (C-X-C 
motif) ligand 10 
  
 
BT.27760.1.S1_
AT 
BoLA /// 
BOLA-A 
major 
histocompatibility 
complex, class I, A /// 
major 
histocompatibility 
complex, class I, A 
  
 
BT.29815.1.S1_
X_AT 
BOLA MHC class I heavy 
chain 
  
 
BT.29820.1.S1_
S_AT 
BOLA MHC class I heavy 
chain 
  
 
BT.3805.1.S1_
AT 
BOLA-N /// 
JSP.1 /// 
LOC1001259
16 
MHC class I antigen 
/// MHC Class I 
JSP.1 /// 
uncharacterized 
protein 100125016 
  
 BT.49.1.S1_AT CD40LG CD40 ligand   
 
BT.9504.1.A1_
AT 
CCL4 chemokine (C-C 
motif) ligand 4 
  
 
BT.9974.1.S1_
AT 
CCL3 chemokine (C-C 
motif) ligand 3 
  
Chemokine BT.155.1.S1_A IL8 interleukin 8 5.42E-04 24.18039
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BT.16966.1.S1_
AT 
CXCL10 chemokine (C-X-C 
motif) ligand 10 
  
 
BT.9504.1.A1_
AT 
CCL4 chemokine (C-C 
motif) ligand 4 
  
 
BT.9974.1.S1_
AT 
CCL3 chemokine (C-C 
motif) ligand 3 
  
Locomotory 
behavior 
BT.155.1.S1_A
T 
IL8 interleukin 8 0.0013878
06 
9.982954
545 
 
BT.16966.1.S1_
AT 
CXCL10 chemokine (C-X-C 
motif) ligand 10 
  
 
BT.5408.1.A1_
AT 
UCHL1 ubiquitin carboxyl-
terminal esterase L1 
(ubiquitin 
thiolesterase) 
  
 
BT.9504.1.A1_
AT 
CCL4 chemokine (C-C 
motif) ligand 4 
  
 
BT.9974.1.S1_
AT 
CCL3 chemokine (C-C 
motif) ligand 3 
  
Inflammator
y response 
BT.155.1.S1_A
T 
IL8 interleukin 8 0.0016045
08 
9.598994
755 
 
BT.16966.1.S1_
AT 
CXCL10 chemokine (C-X-C 
motif) ligand 10 
  
 
BT.49.1.S1_AT UCHL1 ubiquitin carboxyl-
terminal esterase L1 
(ubiquitin 
thiolesterase) 
  
 
BT.9504.1.A1_
AT 
CCL4 chemokine (C-C 
motif) ligand 4 
  
 
BT.9974.1.S1_
AT 
CCL3 chemokine (C-C 
motif) ligand 3 
  
Antigen 
processing 
and 
presentatio
n via MHC 
class I 
BT.27760.1.S1_
AT 
BoLA /// 
BOLA-A 
major 
histocompatibility 
complex, class I, A /// 
major 
histocompatibility 
complex, class I, A 
0.0023599
77 
39.93181
818 
 
BT.29820.1.S1_
S_AT 
BOLA MHC class I heavy 
chain 
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BT.3805.1.S1_
AT 
BOLA-N /// 
JSP.1 /// 
LOC1001259
16 
MHC class I antigen 
/// MHC Class I 
JSP.1 /// 
uncharacterized 
protein 100125016 
  
 
BT.29815.1.S1_
X_AT 
BOLA MHC class I heavy 
chain 
  
B cell 
proliferatio
n 
BT.23172.1.S1_
AT 
BAX BCL2-associated X 
protein 
0.0337752
778987117 
57.04545
4545454
5 
 BT.49.1.S1_AT CD40LG CD40 ligand   
Cell 
adhesion 
molecules 
(CAMs) 
BT.2129.1.S1_
AT 
LOC1008500
64 
versican core 
protein-like 
0.0387712
05 
5.105943
152 
 
BT.29820.1.S1_
S_AT 
BOLA MHC class I heavy 
chain 
  
 
BT.3805.1.S1_
AT 
BOLA-N /// 
JSP.1 /// 
LOC1001259
16 
MHC class I antigen 
/// MHC Class I 
JSP.1 /// 
uncharacterized 
protein 100125016 
  
 BT.49.1.S1_AT CD40LG CD40 ligand   
 
BT.29815.1.S1_
X_AT 
BOLA MHC class I heavy 
chain 
  
Regulation 
of secretion 
BT.27043.2.S1_
AT 
FCER1A Fc fragment of IgE, 
high affinity I, 
receptor for; alpha 
polypeptide 
0.0482075
57 
8.319128
788 
 BT.49.1.S1_AT CD40LG CD40 ligand   
 
BT.29009.1.A1_
AT 
RYR3 ryanodine receptor 3   
 
a The gene enrichment analysis was performed using DAVID bioinformatics tool 6.7 (NIAID/NIH, 
USA). Only genes with a known GO and belonging to the most relevant functional categories 
are reported in the list. 
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To evaluate to what extent gene expression alterations in blood were related to the 
preclinical or clinical stage of the disease, two distinct statistical analyses were 
performed comparing each group with the control one: clinical versus control group 
(CvsCtrl) and preclinical versus control group (PvsCtrl). In the clinical stage, a total of 
207 probe sets showed significant alteration in gene expression levels compared to the 
control group. Among these, 87 were up-regulated while 120 had a reduction in 
expression. Interestingly, a pronounced alteration in the gene expression profile was 
also found in the preclinical stage, with a total number of 113 differentially expressed 
probe sets (55 genes were up-regulated while 58 were down-regulated). Two heat 
maps representing the differentially expressed probe sets in preclinical and clinical 
cattle are shown in Figure 3. The complete probe set lists with the relative p values and 
fold changes can be found in S1 and S2 Tables attached to this thesis. 
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Figure 3. Heat maps representing the DEGs found in clinical and preclinical cattle with 
atypical BSE. Two heat maps were generated using the heatmap.2 function from the gplots 
library in R statistical environment. DEGs were hierarchically clustered with complete linkage 
using the Euclidean metric. The heat maps represent the most significant DEGs (p value ≤.0.05 
and fold change ≥ 2) in clinical (A) and preclinical (B) animals compared to the control group. 
Animals are reported in the x-axis while the differentially expressed probes are in the y-axis. 
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A gene enrichment analysis was performed to identify the most enriched GO terms in 
the clinical and preclinical groups (Figure 4). The preclinical stage was characterized by 
enrichment in gene clusters related to chemokine signaling pathway, extracellular 
region, secreted protein, immune response, pyridoxal phosphate binding, transcription, 
myeloid-associated differentiation marker, B cell proliferation, extracellular matrix, RNA 
metabolic process, MHC class I, Laminin G and response to wounding (Figure 4A). 
DEGs specific of the clinical group were clustered in functional categories related to 
cytokine-cytokine receptor interaction, regulation of leukocyte activation, inflammatory 
response, autoimmune thyroid disease, chemokine activity, B cell proliferation and 
differentiation, regulation of apoptosis, kinase inhibitor activity, and membrane raft 
(Figure 4B).  
A
 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
response to wounding
Laminin G
MHC class I, alpha chain, C-terminal
regulation of RNA metabolic process
extracellular matrix
B cell proliferation
myeloid-associated differentiation…
transcription
pyridoxal phosphate binding
immune response
signal
secreted
extracellular region
chemokine signaling pathway
-log (P value) 
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B
Figure 4 Gene enrichment analysis of DEGs specific  of the clinical and preclinical stage 
of the disease. The most relevant GO terms (y axis) associated to preclinical (A) and clinical 
(B) phase are listed according to decreasing statistical significance from top to bottom. The 
threshold for statistical significance is marked by the orange lines. The enrichment analysis was 
performed using DAVID bioinformatics tool 6.7 (NIAID/NIH, USA).  
When comparing the differentially regulated probe sets identified in the preclinical and 
clinical groups, it was found that 35 differentially expressed probe sets (corresponding 
to 32 DEGs) were common between the two stages of disease (Figure 5), leaving 172 
DEGs specific to clinical and 78 genes specific to preclinical animals. Remarkably, all of 
the 32 common DEGs displayed a very similar pattern of expression in the clinical and 
preclinical groups, as shown in Figure 5B. These genes are listed in bold in S1 and S2 
table attached to this thesis. 
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Figure 5. Identification of common DEGs in blood of preclinical and clinical atypical BSE-
infected cattle. Venn diagram showing the number of differentially expressed probe sets in 
blood of clinical and preclinical cattle. The intersection in grey represents 35 differentially 
expressed probe sets corresponding to 32 differentially expressed genes (DEGs) that are in 
common between the two stages of the disease (A). Expression pattern of the common 32 
DEGs. The histograms represent the fold change relative to the control group. PvsCtrl= 
preclinical versus control, CvsCtrl=clinical versus control (B). 
To further dissect gene expression alterations during the progression of the disease, we 
performed a statistical analysis to identify specific changes between the clinical and 
preclinical stages (CvsP). Indeed, we found 235 DEGs, which were significantly 
enriched in pathways related to immune response (regulation of B cell proliferation, 
leucocyte activation, ISG15-protein conjugation and chemokine signaling were among 
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the most significant). The list of the most relevant enriched probe sets can be found in 
S3 Table attached to this thesis.  
We used a Venn diagram to compare the DEGs found in PvsCtrl, CvsCtrl and CvsP 
analyses that were previously performed and then we examined the expression levels 
of common DEGs (Figure 6). Venn diagram revealed the presence of one DEG in 
common between PvsCtrl, CvsCtrl and CvsP comparisons, while 22 genes were 
differentially expressed in PvsCtrl and CvsP but not in CvsCtrl comparisons (Figure 
6A). We found that these 22 DEGs had an opposite fold change sign in PvsCtrl and 
CvsP, thus indicating an up/down-down/up pattern of expression (see Figure 6B, 6C 
and Table 7). In particular, 9 out of 22 DEGs were up-regulated in the preclinical phase 
and then went back roughly to the expression level of the controls in the clinical stage 
(Figure 6B). The remaining 13 out of 22 DEGs were down-regulated in the preclinical 
phase and then went back almost to control levels in the clinical phase (Figure 6C). The 
only gene in common between the three comparisons, namely Sel-1 Suppressor Of Lin-
12-Like 3 (SEL1L3), was progressively down-regulated during the preclinical and the 
clinical phase of the infection, as shown in Figure 6D. 
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Figure 6. DEGs in common between CvsP, PvsCtrl and CvsCtrl comparisons. (A) Venn 
diagram revealed the presence of 22 DEGs in common between CvsP and PvsCtrl 
comparisons. One DEG (SEL1L3, Sel-1 Suppressor Of Lin-12-Like 3) was common in the three 
comparisons. (B-C) The normalized expression values of the 22 common DEGs for CvsP and 
PvsCtrl comparisons are represented by the histograms. As indicated by the schematic figures 
on the right, these 22 DEGs showed an up/down-down/up pattern of expression: (B) 9/22 were 
upregulated in PvsCtrl and then downregulated in CvsP comparisons, while (C) 13/22 were 
downregulated in PvsCtrl and upregulated in CvsP comparison, respectively. (D) SEL1L3, the 
only gene found in common among the three comparisons (CvsP, CvsCtrl and PvsCtrl), showed 
a progressive downregulation during the preclinical and the clinical phase of the infection. 
P=preclinical, C=clinical and Ctrl=control, vs=versus. DEGs=differentially expressed genes.  
Table 7. List of DEGs characterized by an up-down/down-up pattern of expression.a 
Probe Name Gene Symbol Gene Name Fold Change 
in PvsCtrl 
Fold Change 
in CvsP 
Bt.611.1.S2_at CXCL2 chemokine (C-X-C motif) 
ligand 2  
20.968  -35.428 
Bt.5021.1.S1_at FBN1 fibrillin 1 5.661 -4.474 
Bt.18013.1.A1_at RERE arginine-glutamic acid 
dipeptide (RE) repeats 
3.399 -2.668 
Bt.18234.1.S1_at IGSF6 immunoglobulin superfamily, 
member 6 
-3.289 2.812 
Bt.15334.2.A1_at STAT3 Signal transducer and 
activator of transcription 3  
-3.238 2.679 
Bt.20833.3.A1_at NHLRC2 NHL repeat containing 2 2.825 -2.435 
Bt.27161.1.A1_at C16H1orf114 chromosome 16 open reading 
frame, human C1orf114 
2.783 -2.035 
Bt.17789.1.A1_at ST8SIA4 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 4 
-2.771 5.522 
Bt.21221.1.S1_at LST1 leukocyte specific transcript 1 -2.555 2.531 
Bt.3780.1.S1_at C10H5orf13 chromosome 10 open reading 2.481 -2.248 
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frame, human C5orf13 
Bt.9841.1.S1_at MIR21 microRNA mir-21 -2.452 3.249 
Bt.18474.2.A1_at SHOC2 soc-2 suppressor of clear 
homolog (C. elegans) 
-2.406 3.303 
Bt.21868.2.S1_at IGSF6 immunoglobulin superfamily, 
member 6 
-2.341 2.568 
Bt.27421.1.S1_at ARHGEF2 Rho/Rac guanine nucleotide 
exchange factor (GEF) 2 
-2.263 2.640 
Bt.16088.1.A1_at MYO5C myosin VC 2.261 -2.646 
Bt.1711.1.A1_at LOC615263 uncharacterized LOC615263 -2.203 2.512 
Bt.22390.1.S1_at HPS3 Hermansky-Pudlak syndrome 
3 
2.147 -2.131 
Bt.1847.1.S1_at LOC789748 Sialic acid-binding Ig-like 
lectin 14-like 
-2.125 2.459 
Bt.2334.1.S1_at CD68 CD68 molecule -2.116 2.157 
Bt.26430.1.S1_at ZNF184 zinc finger protein 184 2.099 -2.319 
Bt.1736.1.A1_at SOCS1 suppressor of cytokine 
signaling 1 
-2.061 2.221 
Bt.5878.2.S1_at SDS serine dehydratase -2.027 2.368 
a For each gene the fold changes found in PvsCtrl (preclinical versus control) and CvsP (clinical 
versus preclinical) comparisons are reported. 
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3.3 Selection of the target and reference genes for the RT-
qPCR validation analysis 
 
To confirm the array results using an independent and more sensitive technique, we 
performed RT-qPCR analyses based on SYBR® green assay for a subset of DEGs. The 
selection of the genes to be validated was made on the basis of their p value, fold 
change, and possession of an interesting function as indicated by the enrichment 
analysis or according to the literature. Moreover, because we performed several 
statistical analyses of the microarray data (IvsCtrl, PvsCtrl, CvsCtrl and CvsCtrl), we 
chose genes that appeared as differentially expressed with the highest frequency in 
different resulting datasets. The list of target genes selected for the validation is 
reported in Table 8. Genomic DNA amplification (RT- control), primer dimer 
amplification (NTC control) and yield of signal intensities (Cq values) were carefully 
examined in order to select the best primer pairs for all the genes examined in this 
study. Also, primer specificity was assesed by agarose gel electrophoresis of the RT-
qPCR amplicons.     
Table 8. Candidate target genes analyzed by RT-qPCRa 
Gene Primer sequence 
Amplicon 
length (bp) 
Accession 
number 
CD40L F: ACA ACC TCT GTT CTC CAG TG 82 NM_174624.2 
  R: GTC GTT TCC CGT TTT CGA GG   
XIST F: GTG GCA AGG ACC AGA ATG GA 112 NR_001464.2 
  
R: TCC GAC CCC AGT ATT AGC CA 
  
GNLY F: AGC CCG ATG AGA ATA CCG TT 120 NM_001075143.1 
  
R: CGA TGT CCT CAG CGA TGG TA 
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PDK4 F: TGG TGT TCC CCT GAG AGT CA 109 NM_001101883.1 
  
R: GTA ACC AAA ACC AGC CAG CG 
  
HBA2 F: ACA AGG GCA ATG TCA AGG CC 124 NM_001077422.3 
  
R: TCG AAG TGG GGG AAG TAG GT 
  
GNB4 F: AGA TCG TGC AGG TGT TCT TG 96 NM_001099033.1 
  
R: CTG TCC CAA GAC CCT GTT G 
  
IDO1 F: ATT GGT GGA GTC CCT GCA GAC 150 NM_001101866.2 
  
R: CTG CAG GGT AGC ATT GCC TT 
   
BOLA F: CTC GTA GTA GCT GTG GTG GC 96 NM_001038518.1 
 
R: ACT GTC ACT GCT TGC AGC C 
  
SEL1L3 F: TGA AGG AGT GGTTTC GCC TG 79 NM_001206556.2 
 
R: TTC AAA TCC TGC CCA GTG CT   
a Primers (F, forward; R, reverse) used for gene amplification, amplicon size, and GenBank® 
accession numbers for the bovine cDNA sequences used for primer design. All primers were 
designed according to the genome sequence of Bos taurus.  
 
For the reference genes selection, we outlined a list of possible candidates based on 
blood transcriptomics literature and on previous experiments carried out in our 
laboratory (Gubern, Hurtado et al. 2009, Stamova, Apperson et al. 2009, Ledderose, 
Heyn et al. 2011, Barbisin, Vanni et al. 2014). We designed primer pairs corresponding 
to six of these genes: DECR1 (2,4-dienoyl CoA reductase 1, mitochondrial), GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase), HMBS (hydroxymethyl-bilane synthase), 
FPGS (folylpolyglutamate synthase), RPL12 (ribosomal protein L12) and SDHA 
(Succinate dehydrogenase complex, subunit A). Based on the level of expression 
assessed by a preliminary RT-qPCR analysis, we first selected two genes from the 
above mentioned list. RPL12 and GAPDH were the most robust reference genes (see 
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Figure 7A). We tested these genes on additional samples and noticed that in some 
case the RT- negative control for GAPDH was amplified with a Cq value (threshold 
cycle) too close to that of the RT+ samples. Therefore, we designed two new primer 
pairs for GAPDH that worked better in our conditions (Figure 7B) 
A 
 
B 
 
 
Figure 7. Reference genes selection and GAPDH primer optimization. The expression level 
of 6 candidate reference genes (RPL12, GAPDH, SDHA, HMBS, FPGS and DECR1) was 
assessed by RT-qPCR. RPL12 and GAPDH were selected as they displayed the lowest Cq 
values (A). Primer pair for GAPDH (GAPDH_1) was optimized to reduce the detection of 
genomic DNA. GAPDH_ is the new optimized primer pair that we used for subsequen analyses. 
In red are shown the amplification curves of the RT- control and in green those relative to the 
RT+ sample (B). 
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To verify if our sample population was characterized by an uniform expression of the selected 
reference genes, we performed an RT-qPCR analysis measuring the Cq value for GAPDH and 
RPL12 across all the samples. As shown in Figure 8, the expression trend of GAPDH and 
RPL12 was quite similar. The stability of the two genes was comparable between preclinical, 
clinical and control population, with Cq ranges quite similar among the three groups. In all the 
samples GAPDH was less expressed compared to RPL12, with the exception of sample S1. 
The variability of the reference genes, measured as standard deviation (SD) of the Cq values, 
was slightly higher for GAPDH (SD=1.19) compared to RPL12 (SD=0.98).  
 
Figure 8. Variability of Cq values among preclinical, clinical and control samples. 
 
At this point we performed a preliminary RT-qPCR analysis on a subgroup of samples 
(4 preclinical, 4 clinical and 4 control) to verify that the results obtained normalizing with 
RPL12 and GAPDH were comparable. As target genes to test in this preliminary 
analysis, we selected GNLY and GNB4. Concerning GNLY, we found that the ΔΔCq 
values were quite similar using GAPDH and RPL12 as reference. However, for GNB4 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
A
v
e
ra
g
e
 C
q
 
GAPDH
RPL12
85 
 
the results changed more consistently depending on the reference gene used for the 
normalization (Figure 9).  
A 
 
B 
 
Figure 9. GNLY (A) and GNB4 (B) ΔΔCq values in preclinical and clinical samples using 
GAPDH or RPL12 as reference genes. 
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3.4 Optimization of the RT-qPCR normalization method. 
 
Since a considerable grade of variability of the results was found using GAPDH or 
RPL12 as control gene, we decided to introduce a third one (ACTB, beta actin) and to 
adopt a normalization factor based on geometric averaging of the three selected 
reference genes. In this way we could improve the accuracy of the analysis and avoid 
erroneous interpretation due to the variability associated to the use of a single reference 
gene per time (Vandesompele, De Preter et al. 2002). Moreover, we included in our 
study two inter-run calibrators to reduce plate to plate variability. The stability of the 
selected reference genes was determined by calculating their geNorm M value (M) and 
the coefficient of variation (CV) on the normalized relative quantities (Figure 10) 
(Hellemans, Mortier et al. 2007). M and CV values were then compared against 
empirically determined maximum thresholds for acceptable stability (~ 1 and ~ 0.5 for M 
and CV values, respectively) (Hellemans, Mortier et al. 2007). The statistical analysis 
and the fold change calculation for the final analyses were carried out using qBasePlus 
1.1 software (Hellemans, Mortier et al. 2007).  
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3.5 Setting of the minimal RNA starting amount for RT-qPCR 
amplification. 
 
Since we had a limited quantity of RNA for each sample, before proceeding with 
subsequent analyses we had to set the minimal RNA template amount for the RT-qPCR 
analysis. Based on previous protocols used in our laboratory, we decided to test two 
different RNA concentrations: 1.25 ng/µL and 0.625 ng/µL, corresponding to a dilution 
of 1:10 and 1:20 of the initial RNA, respectively. For this preliminary experiment we 
used 1 µL of RNA solution and two primer pairs which amplified a reference gene 
(RPL12) and a target gene (GNB4). Forward and reverse primers were used at a 
concentration of 400 nM each. The results showed that these two different RNA amount 
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Figure 10. Reference gene expression stability. Stability of the selected reference genes 
was determined by calculating their geNorm M value (M) (A) and their coefficient of variation 
(CV) (B) on the normalized relative quantities (CNRQ). The dashed green lines in panel A and 
B indicate the maximum acceptable threshold for M and CV values, respectively. These 
thresholds have been empirically determined by previous experiments performed by 
Hellemans and colleagues (Hellemans, Mortier et al. 2007) 
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resulted in around 1 Cq difference between the two amplification curves, as expected 
(Figure 11). Amplification of the target gene GNB4 resulted in a Cq equal to 30.96 and 
32.13 using 1.25 and 0.625 ng as starting RNA amount, respectively. Such Cq values 
were quite high if we consider that 30-35 Cq is the generally accepted maximum 
threshold for a reliable quantification. For this reason, we decided to use the higher 
RNA starting amount (1.25 ng) for all the subsequent RT-qPCR analyses. 
 
Figure 11. Mean Cq values for RPL12 and GNB4 using two different RNA starting 
amounts. 
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3.6 RT-qPCR final results. 
 
We performed RT-qPCR analysis for all the genes reported in Table 8. We were able to 
confirm the microarray results for six out of nine genes selected (XIST, CD40L, GNLY, 
PDK4, HBA2 and SEL1L3), which are represented in Figure 12 and Table 9: CD40L, 
XIST, SEL1L3 and GNLY downregulation was confirmed in both preclinical and clinical 
groups, while HBA2 was significantly down-regulated only in preclinical animals. 
Significant PDK4 upregulation was found in the clinical stage, but not in the preclinical 
one. These results were in line with the microarray data (Table 9). 
 
Figure 12. Validation of microarray data by RT-qPCR. Differential expression of selected 
genes in blood from preclinical (A) and clinical (B) atypical BSE-infected cattle. Ganulysin 
(GNLY), X-inactive specific transcript (XIST), pyruvate dehydrogenase kinase 4 (PDK4), CD40 
ligand (CD40L), haemoglobin, alpha 2 (HBA2) and Sel-1 Suppressor Of Lin-12-Like 3 protein 
(SEL1L3). Gene expression (ratio) values are represented as relative to RNA levels in control 
animals. Ns = not significant; *P value ≤ 0.05. 
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Table 5. Differential expression of selected genes quantified by microarray and 
RT-qPCR analysis a. 
Gene name 
Gene 
symbol 
Microarray fold change RT-qPCR ratio/FC 
 
 preclinical clinical preclinical clinical 
Granulysin GNLY -6.318 -3.698 0.322/-3.106 0.433/-2.309 
X-inactive specific 
transcript 
XIST -33.240 -22.612 0.003/-333.333 0.004/-250.000 
Pyruvate 
dehydrogenase 
kinase 4 
PDK4 1.752 (ns) 5.793 
0.665/ -1.503 
(ns) 
2.536 
CD40 ligand CD40L -2.786 -3.761 0.667/-1.499 0.408/-2.450 
Haemoglobin, alpha 
2 
HBA2 -3.866 (ns) 
-2.259 
(ns) 
0.269/-3.717 
0.816/-1.225 
(ns) 
Suppressor Of Lin-
12-Like Protein 3 
SEL1L3 -2.16 -5.17  0.504/-1.984 0.213/-4.695 
a For an easier interpretation, the differential expression of the downregulated genes measured 
by RT-qPCR is reported both as original ratio and as fold change calculated as -1/ratio. Ns=not 
significant. FC=fold change. 
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4 Discussion 
Whilst the major neuropathological features of TSEs are well documented, the host 
response to prion infection and the molecular events that characterize the peripheral 
prion pathology are largely unknown. Genomic approaches are a potential tool to 
understand the molecular bases of complex mechanisms such as prion disorders. 
Further, they are powerful tools for the identification of target genes that could be used 
as disease biomarkers. Indeed, one of the major challenges in the field of 
neurodegenerative diseases is the finding of a preclinical diagnostic test that would 
allow the patient to begin therapy before irreversible neuronal loss has occurred. An 
early treatment could increase the possibility to slow disease progression and perhaps 
even reverse it. In prion disorders, such as vCJD or BSE, the development of a 
preclinical test is particularly desirable due to their transmissible nature, even at early 
stages of the infection. 
In the present study, gene expression changes occurring in the blood of atypical BSE-
infected cattle were identified with the aim to understand the peripheral mechanisms of 
prion infection and to detect some candidate genes that could be further investigated as 
biomarkers of the disease. Since our aim was to find a common pattern in H- and L-type 
infection, we pooled these two groups. Indeed, in a preliminary analysis we compared 
the 4 H-type and the 4 L-type infected animals and found a limited number of DEGs. 
Therefore, we concluded that, at least in terms of number of DEGs, these two groups 
did not display large differences. This observation is in agreement with a previous work 
of Konold and colleagues, which carried out a behavioral study on the same animals 
that we used in our analysis (Konold, Bone et al. 2012). In their study it was also found 
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a large similarity between the 4 H-type and the 4 L-type infected groups in terms of 
behavioral and clinical signs. Also, another study by Priemer and colleagues highlighted 
a similarity between H and L type BSE (Priemer, Balkema-Buschmann et al. 2013). 
Indeed they found comparable PrPSc anatomical distribution for atypical strains, with 
only slight differences in the overall intensities between L- and H-type. Taking into 
account all these considerations, we decided to focus our attention on finding a 
common gene pattern among all the atypical BSE-infected cattle and therefore we 
pooled the two groups. Further studies in larger animal cohorts would be required to 
investigate in detail the strain-specific gene expression changes occurring during the 
progression of the disease.  
During the last decade, several high-throughput genomic profiling studies have been 
performed on murine, ruminant and primate models. The majority of these studies 
focused on the gene expression changes occurring in the CNS in course of prion 
infection. However, despite being informative of the central disease mechanisms, direct 
analyses of the brain or spinal cord are not suitable for rapid diagnosis of infected 
animals and patients. To our knowledge, we present here the first microarray study of 
whole blood from BSE-infected cattle. Whole blood is an accessible source of 
transcriptional information and offers many advantages compared to blood fractioning, 
such as minimization of sample handling artifacts, reduction of sample variability due to 
fractionation and a shorter protocol. One of the major caveats in using peripheral blood 
is that its cellular components may change dramatically during infections or 
inflammation. The animals used in the present study did not show any apparent side 
pathology, they were monitored daily by the husbandry staff and their blood was 
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examined for serum aspartate aminotransferase (AST), creatine kinase (CK) and 
manganese (Konold, Bone et al. 2012). Nonetheless, possible interference due to 
hidden pathologies or to inter-individual variations in hematocrit and white blood cell 
count may affect interpretation of expression data and should be considered as an 
important variable in future studies. In light of this, the present results should be read as 
a first attempt to explore whole blood transcriptomics in course of a prion infection.  
A comparison of our results with other studies would be important to identify the most 
promising signature genes of the disease to be further tested in larger cohorts and in 
other animal models. Unfortunately, at present very little information is available on 
gene expression changes related to atypical BSE infections.  In 2011 Panelli et al. 
(Panelli, Strozzi et al. 2011) investigated the gene expression changes in fractionated 
white blood cells from L-type orally-infected cattle. In this study 56 DEGs were identified 
using a custom array.  Surprisingly, only a few of them were present in our list as well. 
Different infection routes, microarray platforms, statistical analysis stringency and p 
value cut-off may explain such discrepancy. Additionally, the white blood cells used in 
the study of Panelli et al. were isolated from 1 year post-infection animals, while in our 
study we used whole blood from preclinical and clinical infected cattle (at 6 months and 
22-26 months post-infection, respectively). Finally, in addition to leukocytes, whole 
blood contains many cell populations such as immature dendritic cells, erythrocytes with 
residual transcription activity (Kabanova, Kleinbongard et al. 2009) and platelets, which 
may respond to prion infection by regulating different sets of genes. 
The scavenger receptor CD163L1 (CD163-like molecule 1) was one of the genes found 
upregulated in both our and Panelli’s study (we found significant changes in IvsCtrl and 
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LvsCtrl). CD163 is a member of the scavenger receptor cysteine-rich (SRCR) 
superfamily class B that is highly expressed on resident tissue macrophages and 
monocytes. Besides a function as innate immune sensor for bacteria and inducer of 
local inflammation (Fabriek, van Bruggen et al. 2009), CD163 play a role in 
erythropoiesis (Fabriek, Polfliet et al. 2007) and has been identified as an endocytic 
receptor for hemoglobin-haptoglobin (Hb-Hp) complexes (Kristiansen, Graversen et al. 
2001). These findings are interesting especially in light of previous data reporting the 
differential expression of an erythroid differentiation-related factor (EDRF) that was 
suggested as a possible molecular marker for early stages of TSE infection (Miele, 
Manson et al. 2001). In this context, it is of note that a therapeutic strategy focused on 
hematopoietic cells was able to suppress the pathological effects of Sandhoff disease, a 
neurodegenerative pathology that, in a similar manner to TSEs, present inflammatory 
response involving microglial activation that leads to neuronal apoptosis (Wada, Tifft et 
al. 2000). The involvement of the hematopoietic system in prion infection is also 
supported by the HBA2 downregulation that we confirmed in the preclinical stage of 
prion infection by RT-qPCR analysis. Haemoglobins are iron-containing proteins that 
transport oxygen in the blood of most vertebrates. Beside blood, HBA and HBB are also 
expressed in mesencephalic dopaminergic neurons and glial cells (Biagioli, Pinto et al. 
2009) and are down regulated in AD, PD and other neurodegenerative diseases 
(Kabanova, Kleinbongard et al. 2009). Haemoglobin gene expression alteration during 
preclinical scrapie was also found in the spleen and CNS of infected animals (Booth, 
Bowman et al. 2004, Kim, Snyder et al. 2008), as well as in the brains of nonhuman 
primates infected with BSE (Barbisin, Vanni et al. 2014). Further, it has been found that 
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both HbA and HbB protein distribution is altered in mitochondrial fractions from PD 
degenerating brain (Shephard, Greville-Heygate et al. 2014). Taken together, these 
findings strongly suggest a central role for haemoglobin in neurodegenerative 
processes. 
An aspect to be taken into account when reading the present results is that additional 
negative control cattle, aged from 12 to 37 months and derived from a different herd 
compared to the Konold’s study group (Konold, Bone et al. 2012) were introduced in the 
analyses. The addition of these controls was useful to balance the samples from 
infected animals and allowed a preliminary exploration of the differentially expressed 
transcripts. However, age-related and environmental variability may have affected to 
some degree the data and need to be further considered for their correct interpretation. 
Despite some limitations, since several statistical analyses were performed (including 
the CvsP comparison, in which all the animals derived from the same herd) a cross 
comparison of all them, as we did with the Venn diagram, is useful in order to define a 
set of genes for further validation. In light of this, we believe that our data constitutes an 
important starting point for future experiments. 
A technical issue that we had to solve in the present study consisted in the fact that the 
RNA samples that we received were very low concentrated, even after reducing the 
final RNA elution volume. According to the standard one-cycle amplification and labeling 
protocol developed by Affymetrix (Santa Clara, CA), a minimal mRNA concentration is 
required to perform the RNA target preparation for the microarray experiments. 
According to this protocol, the recommended input RNA amount should be equal to 100 
ng in a volume smaller than 3 µL. Many of our samples had a concentration lower than 
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this threshold, prompting us to concentrating them. It is known that such a procedure 
may affect the final integrity of the samples, especially when long time and/or high 
temperature conditions are set for the concentration. However, the protocol that we 
adopted was specifically designed to speed up the evaporation of solvents from very 
small samples and is commonly used in this field, especially when the 260/280 and 
260/230 ratios are good, as for our samples; thus we did expect that the concentrate 
would adequately represent the initial mRNA products. Further, all our samples were 
processed in the same way, at room temperature and for a very short time (around 5 
minutes). Their integrity was assessed by capillary electrophoresis and was found to be 
mostly unchanged than before concentration. 
In the first statistical analysis we performed (IvsCtrl), we found that among 101 DEGs, 
93 had known functions and were involved in several biological processes and 
molecular pathways, such as autoimmune thyroiditis, chemokine and cytokine activity, 
regulation of the secretion pathway, immune system components and antigen 
processing presentation. Previous studies on CNS tissues from BSE-infected animals 
also showed the involvement of many of these pathways in prion pathogenesis. For 
example, a decrease in GNLY expression, which we could validate in both the 
preclinical and clinical group, was also found in the medulla oblongata from preclinical 
sheep affected by natural scrapie (Filali, Martin-Burriel et al. 2012). GNLY is a powerful 
antimicrobial protein contained within the granules of cytotoxic T lymphocyte and natural 
killer cells. Its downregulation could be interpreted as a mechanism exerted by prions to 
escape the immune system and could contribute to explain a lack of NK activation 
during the course of prion infection.  
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The similarity between brain and blood –omics is not surprising, since it has already 
been established in the literature that blood transcriptomics can identify genes that are 
relevant to the pathological processes occurring in the CNS (Tylee, Kawaguchi et al. 
2013). Indeed, measuring disease-related gene expression in peripheral blood may be 
a useful proxy measure for gene expression in the CNS (Borovecki, Lovrecic et al. 
2005, Tylee, Kawaguchi et al. 2013). Nonetheless, transcriptional changes occurring in 
blood do not always overlap with those found in the brain, a fact that does not 
necessarily detract from their suitability as indicators of CNS pathology. For example, 
an increase in CCL3 and CCL4 chemokine expression was observed in CJD infected 
mouse brains during preclinical stage of the disease (Lu, Baker et al. 2004), while in our 
study we found a downregulation for such genes (CCL3 downregulation was found in 
IvsCtrl and CvsCtrl comparison while CCl4 was found downregulated in CvsCtrl). 
Interestingly, it has been shown that these chemokines are involved in the migration of 
bone marrow-derived mesenchymal stem cells to brain lesions caused by prions (Song, 
Honmou et al. 2011).  Thus, we could hypothesize that a reduction of their expression in 
the periphery paralleled by an increase in the CNS could be relevant in this migration 
phenomenon. As for CCL3 and CCL4, we found downregulation for CCL5, a chemokine 
involved in the activation of NK cells. The lack of reported NK cell response to prion 
pathogenesis suggests that the reduction of CCL5 expression, together with the already 
mentioned GNLY downregulation, may be the consequence of a prion-induced 
mechanism to evade NKs.  
An interesting DEG found by microarray analysis in IvsCtrl was IDO1 (indoleamine 2,3-
dioxygenase 1). IDO1 is a heme-containing protein that acts as a rate-limiting enzyme 
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of tryptophan catabolism through kynurenine pathway. Metabolites in the kynurenine 
pathway, generated by tryptophan degradation, are thought to play important roles in 
neurodegenerative disorders, including Alzheimer’s and Huntington’s diseases. Notably, 
it has been shown that kynurenine 3-monooxygenase inhibition in the blood ameliorates 
neurodegeneration (Zwilling, Huang et al. 2011). Microarray analysis performed in the 
present study revealed a downregulation for IDO,1 but RT-qPCR analysis did not 
confirm this result. 
To characterize the gene expression profile in the preclinical and clinical stages, we 
performed the PvsCtrl and the CvsCtrl statistical comparisons. We found that 113 probe 
sets were differentially regulated in the preclinical stage of the disease, while 207 probe 
sets had an altered expression in the clinical phase. Importantly, the present results 
indicated that, at least in blood, a consistent gene expression alteration is present from 
the early stages of the disease. This finding is in agreement with microarray analysis 
carried out by Tang et al., which revealed the highest degree of differential gene 
regulation in brains of cBSE-infected cattle at 21 months post infection, which  is prior to 
the detection of infectivity (Tang, Xiang et al. 2009). Also, Tortosa and colleagues found 
a significant number of DEGs at early stages of the disease in the CNS from cBSE-
infected transgenic mice (Tortosa, Castells et al. 2011).  
Venn diagram revealed that 35 DEGs were in common between the clinical and 
preclinical groups and, remarkably, they had a very similar pattern of expression in both 
stages of the disease. The fact that these genes are altered in both subgroups of 
infected animals should be read as an internal comparison which may help in the 
identification of the most promising candidate genes for further validation experiments. 
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Based on GO enrichment analysis, we found that immunity and inflammation processes 
were strongly involved during the progression of the disease stages. Expression of 
many chemokines was altered in both the preclinical and clinical groups. Besides the 
aforementioned chemokines of the C-C family, we also found a downregulation of 
CXCL10 (IvsCtrl and CvsCtrl analyses) CXCL3 (PvsCtrl analysis), CXCR6 (IvsCtrl, 
PvsCtrl and CvsCtrl analyses) and CXCR5 (CvsCtrl and SvsP analyses). CXCL3 
controls the migration and adhesion of monocytes and neutrophils, while CXCR6 is 
found primarily on activated T cells, NKT cells, bone marrow, plasma cells and smooth 
muscle cells. At present, there are no reports in literature indicating any specific role for 
these two chemokines in prion pathophysiology. We can only hypothesize that their 
downregulation could be part of the immune escape strategy exerted by prions in the 
periphery. CXCL10 is known to be a potent chemoattractant for Th1 T cells, NK cells, 
and monocytes/macrophages. Also, it is known as a potent angiostatic factor (Angiolillo, 
Sgadari et al. 1995). Therefore, its downregulation could be read both as an immune 
escape mechanism and as strategy for prion propagation within the organism. Of note, 
expression of CXCR5 has been found to be involved in the regulation of prion 
neuroinvasion. Indeed, CXCR5 ablation juxtaposes FDCs to major splenic nerves, and 
accelerates the transfer of intraperitoneally administered prions into the spinal cord 
(Prinz, Heikenwalder et al. 2003). In light of this evidence, the downregulation of 
CXCR5 also supports the hypothesis of an active process exerted by prions to evade 
and hijack the immune system.  
Interestingly, we found that antigen processing and presentation via MHC (major 
histocompatibility complex) molecules and the autoimmune thyroiditis pathway were 
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significantly altered in atypical BSE-challenged animals. The majority of MHC class I 
molecule coding-genes were down-regulated in infected cattle (three out of four probes) 
and, also, MHC class II molecule coding transcripts were found to be down-regulated 
during the progression of the clinical signs (four out of four probes were down-regulated 
in the CvsP comparison). In line with the trend found by the microarray analysis, the RT-
qPCR validation experiments indicated a downregulation for MHC class I heavy chain 
(BOLA), even though the results failed to reach the statistical significance (data not 
shown). The involvement of MHC transcripts in prion pathogenesis is supported by 
another microarray study published by Khaniya and colleagues (Khaniya, Almeida et al. 
2009).In this study it was found a reduction in the expression of two genes related to 
MHC II and one gene involved in MHC class I presentation in Peyer’s Patches of BSE-
infected cattle. The authors hypothesized that, since MHC class I molecules are 
associated with the development of T cytotoxic cells, by limiting this process the PrPSc-
expressing cells, like macrophages or peripheral blood mononuclear cells (PBMCs), 
may escape immune surveillance.  
Interestingly, gene enrichment of the autoimmune thyroiditis pathway was found in the 
clinical stage of the disease. It is well established in literature that Hashimoto’s 
encephalitis, together with the associated thyroiditis, is a differential diagnosis for CJD, 
since the two pathologies share a very similar clinical symptomatology (Seipelt, Zerr et 
al. 1999). As hypothesized previously by Prusiner and colleagues, the clinical 
similarities between CJD and Hashimoto’s thyroiditis raise the possibility that protein 
misprocessing may underlie both neurodegenerative and autoimmune diseases 
(Prusiner 2001). 
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A fourth statistical analysis was performed to identify any specific changes between the 
clinical and the preclinical stages of disease (CvsP). We found that the last phases of 
the disease were accompanied by the overactivation of several genes involved in the 
immune defense response. In particular, the shift from the preclinical towards the 
clinical stage was characterized by the upregulation of genes involved in B cell 
proliferation and the ISG15 (IFN-induced 15-kDa protein) conjugation system. ISG15 is 
a ubiquitin-like molecule that is tightly regulated by specific innate immunity signaling 
pathways (Blomstrom, Fahey et al. 1986). Interestingly, it has been shown in the 
literature that this protein is over-activated in the spinal cord of amyotrophic lateral 
sclerosis mice models (Wang, Yang et al. 2011) and it has been indicated as a general 
marker for both acute and chronic neuronal injuries (Wang, Kaul et al. 2012). Also, 
some ficolins and PTAFR (platelet-activating factor receptor) were found upregulated in 
CvsCtrl analysis. Ficolins are a group of oligomeric lectins involved in complement 
activation in the absence of antibody binding. Notably, it has been shown that 
complement activation facilitates early prion pathogenesis (Klein, Kaeser et al. 2001). 
On the same line, upregulation of PTAFR could be linked to the spread of prions, since 
activated platelets have been shown to release PrPC on exosomes (Robertson, Booth et 
al. 2006). 
To further analyze the data, we compared the list of DEGs found in PvsCtrl, CvsP and 
CvsCtrl and found 22 genes with an up/down-down/up pattern of expression, being 
differentially expressed in the preclinical stage and then going back roughly to the 
control level in the clinical stage. These genes, in addition to the aforementioned 32-
gene pattern, may be the preferential candidates to be further investigated as diagnostic 
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biomarkers and for monitoring the progression of the disease. Interestingly, some of the 
up/down-down/up DEGs are involved in regulation of transcription, thus suggesting that 
the gene expression during atypical BSE infection is tightly regulated. Venn diagram 
revealed that one gene, SEL1L3, was down-regulated in all the comparisons (PvsCtrl, 
CvsCtrl, CvsP). SEL1L3 codes for a transmembrane protein whose function is 
unknown. Interestingly, an important paralog of SEL1L3, SEL1L, is involved in the 
retrotranslocation of misfolded proteins from the lumen of the endoplasmic reticulum to 
the cytosol, where they are degraded by the proteasome in an ubiquitin-dependent 
manner (Gardner, Swarbrick et al. 2000). Therefore, we could hypothesize that its 
down-regulation in prion-infected animals would lead to a reduced degradation of PrPSc, 
thus supporting the progression of the disease. We validated this gene by RT-qPCR, 
confirming its down-regulation in both the preclinical and clinical stages of the disease. 
Further investigation on the function of SEL1L3L would be of great interest since this 
gene may play an important role in prion disease and maybe other neurodegenerative 
illnesses.   
As shown in the results, the preliminary RT-qPCR analyses were carried out using two 
reference genes as internal controls. However, we had problems in interpreting the 
results since in some case the gene expression changes were quite different depending 
on which gene was used for the normalization.  Probably, when the variation in gene 
expression is very subtle, different fold change values are obtained across different 
reference genes. On the contrary, large gene expression changes are more robust and 
therefore can be detected in a comparable way by different reference genes. To 
overcome this issue, we decided to introduce a third reference gene and to shift from 
103 
 
the classic delta-delta-Ct method to multiple reference genes. In this way we could 
obtain more reliable data and also we had the possibility to evaluate the stability of the 
reference genes by calculating their M and CV value. 
In this last part of the Discussion, we will briefly describe the functions and the possible 
roles in prion pathology of the genes confirmed by RT-qPCR analysis. Besides SEL1L3, 
GNLY and HBA2, which were already mentioned in previous sections of the Discussion, 
another three genes were validated: CD40L, XIST and PDK4.  
 
CD40L was found to be downregulated in both the preclinical and clinical stage, in 
agreement with microarray results. Also, the microarray analysis highlighted a 
downregulation of CD40, the CD40L receptor. CD40–CD40L interactions mediate a 
broad variety of immune and inflammatory responses and have been implicated in the 
pathogenesis of Alzheimer’s disease (AD) (Tan, Town et al. 1999, Calingasan, Erdely et 
al. 2002). Mice deficient for CD40 or CD40L have impaired immunoglobulin class 
switching, lack germinal center formation and are deficient for germinal center B cells 
(GCBs). There are conflicting reports regarding the role of CD40 in prion diseases. A 
rapid disease development was observed in scrapie-infected mice deficient for CD40L, 
thus suggesting a neuroprotective function of intact CD40-CD40L interactions 
(Burwinkel, Schwarz et al. 2004). In line with this, CD40L−/− mice inoculated with ME7 
prions via skin scarification developed disease significantly earlier than did wild-type 
mice(Mohan, Bruce et al. 2005). In contrast, results obtained from CD40L−/− mice 
inoculated via an intraperitoneal route with the Rocky Mountain Laboratory (RML) 
scrapie strain detected no alteration of prion pathogenesis (Heikenwalder, Federau et 
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al. 2007). Although the importance of CD40L in prion disease progression has not yet 
been clarified, its downregulation in blood during both preclinical and clinical stages of 
atypical BSE-infection suggests that prion infection has an impact on the host immune 
system response and that immune tolerance may be an active process induced by 
prions.  
A marked downregulation in XIST expression was found in our infected animals. XIST is 
a gene located on X chromosomes which codes for a long non-coding RNA (LncRNA) 
involved in X-chromosome dosage control (Penny, Kay et al. 1996, Nguyen and 
Disteche 2006). Since XIST mRNA has the same sequence as XIST gDNA, it was 
impossible to design a primer pair that could discriminate between the two. Indeed, RT- 
control for XIST presented quite low Cq values (meaning high expression) compared to 
the other genes that we validated. However, since the genomic contamination was 
uniform among the samples, we still considered the results reliable. LncRNAs are 
emerging as useful biomarkers for neurodegenerative diseases such as AD (Johnson 
2012) and other disease processes (Sun, Wang et al. 2013), and they can be easily 
detected in blood and urine from patients. In addition, we cannot exclude the possibility 
that the alteration in XIST expression may have some role in gender-dependent 
response to prion infection (Loeuillet, Boelle et al. 2010).  
RT-qPCR experiments confirmed the upregulation of PDK4 in clinically affected 
animals. PDK4 encodes for a mitochondrial protein involved in glucose metabolism 
through the inhibition of pyruvate dehydrogenase complex, which leads to a reduction in 
pyruvate conversion to acetyl-CoA (Harris, Bowker-Kinley et al. 2002). In the literature, 
a key role has been suggested for acetyl-CoA fueling for the survival of cholinergic 
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neurons in the course of neurodegenerative diseases (Szutowicz, Bielarczyk et al. 
2013). PDK4 overactivation can lead to a switch from glucose catabolism to fatty acid 
utilization (Zhang, Hulver et al. 2014), thus increasing the production of ketone bodies. 
Notably, it has been shown in the literature that these molecules are able to cross the 
blood brain barrier. We could speculate that in prion infection (or at least in atypical BSE 
infection) the concentration of ketone bodies would rise in blood, as a consequence of 
PDK4 upregulation, and act in the brain as neuroprotective molecules (Reger, 
Henderson et al. 2004, Henderson 2008). This would be an attempt by the organism to 
prevent the neurodegeneration induced by prions.  
 
5. Conclusions 
The present study has led to the identification of several gene expression changes in 
whole blood from atypical BSE infected cattle prior to and after the manifestation of the 
pathology. 35 DEGs were found in common between the preclinical and the clinical 
stage, with all of them displaying a similar expression pattern during the progression of 
the disease. Large differences in blood transcripts were also found in the comparison of 
preclinical and clinical stage, thus suggesting a role of the peripheral immune system in 
the prion-pathogenic mechanisms observed at late stages in the CNS. The comparison 
of all microarray analyses performed in this study led to the identification of a core of 22 
DEGs that displayed an up/down-down/up pattern of expression. Such genes could be 
good candidate markers to be tested in larger animal cohorts and in blood from human 
patients. By comparing our results with other studies on various animal prion diseases, 
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we observed that some of the most significantly altered DEGs we found in blood were 
found differentially expressed also in brain tissue from BSE-infected cattle; this 
observation indicates that whole blood transcriptomics may serve as a proxy measure 
for monitoring the changes occurring in the CNS. Overall, our study confirmed the 
differential expression of 6 genes (XIST, CD40L, GNLY, PDK4, HBA2 and SEL1L3), 
which may play several roles in atypical BSE pathogenesis and, possibly, in other prion 
infections. Indeed, they are involved in multiple pathways such as immune response, 
inflammation, and glucose catabolism, all of which have already been mentioned in 
other studies related to several prion pathogeneses. Even though further studies are 
required to investigate the specific involvement of all the identified genes in prion 
diseases, our data support the idea of a relationship of complicity and tolerance 
between prion and the host immune system. As concluding remark, our study 
underlined the importance of utilizing whole blood, without any additional manipulation, 
as a source tissue for the development of a preclinical diagnostic test. 
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6 Materials and Methods 
All procedures involving animals were approved by the Home Office of the UK 
government according to the Animal (Scientific Procedures) Act 1986 and in conformity 
with the institutional guidelines of the Istituto Zooprofilattico Sperimentale del Piemonte 
Liguria e Valle d'Aosta, Turin, Italy (IZSPLV), that were in compliance with national (D.L. 
no. 116, G.U. suppl. 40, Feb. 18, 1992, Circular No.8, G.U., 14 July 1994) and 
international regulations (EEC Council Directive 86/609, OJ L 358, 1 Dec.12, 1987). All 
the experimental protocols proposed were reviewed and approved by the IZSPLV 
Animal Care and Use Committee (IACUC). 
6.1 Blood samples 
Blood samples from 8 BSE-infected cattle (4 with H-type and 4 with L-type BSE) and 2 
non-infected controls were provided by the Biological Archive Group at the Animal and 
Plant Health Agency (AHVLA), United Kingdom. All procedures involving animals were 
approved by the Home Office of the UK government according to the Animal (Scientific 
Procedures) Act 1986. The calves were born by crossing Aberdeen angus with females 
imported from Denmark (Danish Holstein, Danish milking red). The inoculation details 
have been reported previously (Konold, Bone et al. 2012). Briefly, experimental cattle 
were intracerebrally inoculated with 1 ml of a 10% brain homogenate of either L-type or 
H-type BSE at 10-11 months of age (Konold, Bone et al. 2012). All infected cattle used 
in this study were females. The negative controls were age and sex-matched with the 
infected group. For each animal, the blood sampling was performed at 2 different time 
points after inoculation, corresponding to the preclinical (6 months post-infection) and 
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the clinical (from 22 to 26 months post-infection) stage of the disease. In this way we 
obtained 16 samples, 8 in the preclinical and 8 in the clinical stage. The estimated 
clinical onset after infection was based on the presence of changes in behavior, 
unexpected startle responses, and difficulty in rising (Konold, Bone et al. 2012). 
Neurological examination and behavioral observations were conducted routinely until 
the culling of the animals. TSE infection was confirmed by post-mortem 
immunohistochemistry on brain sections of the animals (Konold, Bone et al. 2012). 
Detailed information on the husbandry procedures and the pathological signs have been 
described in a previous study published by Konold et al. (Konold, Bone et al. 2012). 
Finally, blood samples from 6 sex-matched Aberdeen angus from a different herd were 
added to the study and used as additional negative controls to obtain a sample size 
comparable to the one of the infected animals (8 samples). 
6.3 RNA isolation 
 500 µL of fresh blood were stabilized in 1.3 mL RNAlater® Solution and immediately 
frozen at -20 °C. Samples were sent in dry ice to IZSTO (Turin, Italy), where the RNA 
was isolated according to the RiboPure™-Blood Kit manufacturer’s instructions 
(Ambion®). DNase I treatment (Ambion®) was included in the RNA extraction protocol to 
reduce DNA contamination. Purified RNA was initially eluted in 100 µL elution solution 
and the final concentration, as well as the absence of protein, was determined using a 
Thermo Scientific™ NanoDrop 2000 spectrophotometer. Since the RNA concentration 
was too low to proceed with the subsequent analysis, newly isolated RNA samples were 
eluted in 50 µL elution solution. Again the concentration was low, therefore the RNA 
samples were concentrated using a Labconco CentriVap concentrator. Sample were let 
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evaporate for 5 minutes at room temperature. The new concentration was assessed 
using a Thermo Scientific™ NanoDrop 2000 spectrophotometer and the integrity of the 
RNA was determined by capillary electrophoresis (Agilent 2100 Bioanalyzer, Agilent 
Technologies, Santa Clara, USA). 
6.4 Microarray hybridization, statistical analysis and data 
mining 
 24 RNA samples were used for the microarray analysis: 8 preclinical (P1, P2, P4, P5, 
P7, P8, EP9 and P10), 8 clinical (S1, S2, S3, S4, S7, S8, S9 and S10), and 8 control 
(c2, c3, cP3, c5, cS5, cP6, cS6 and c9) samples. 120 ng of each total RNA were used 
as template for the synthesis of biotin-labeled cRNA according to the standard one-
cycle amplification and labeling protocol developed by Affymetrix (Santa Clara, CA). 
cRNA was then fragmented and hybridized on GeneChip® Bovine Genome Array, which 
contains over 24128 probe sets. The microarrays were washed, stained (Affymetrix 
fluidic station 450 DX) and scanned (Affymetrix scanner 3000 7G). Cell intensity values 
from the raw array data were computed using the Affymetrix GeneChip® Operating 
Software (GCOS). Microarray quality control and statistical analysis were performed in 
the software system R using the Bioconductor package OneChannelGUI (Gautier, Cope 
et al. 2004, Sanges, Cordero et al. 2007, Simmons, Spiropoulos et al. 2011). The 
LIMMA algorithm was used to compute a linear model fit (Smyth 2004). Data filtering 
and normalization was carried out using GC-Robust multi-array analysis (GCRMA) from 
imported Affymetrix data (.CEL) files. After the assessment and inspection of microarray 
quality controls (RNA degradation plot, RLE and NUSE plots) we identified one low 
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quality control sample (cS5) and excluded it from the analysis (see Figure 2). In the 
final analysis the low-quality RNA sample P9 was substituted by the high-quality RNA 
sample EP9, which was purified from blood collected from the same animal.  
Gene probes with a p value ≤0.05 and fold-change ≥2 were considered to be 
differentially expressed. Differentially expressed probe sets were functionally classified 
using David Bioinformatics tool (Huang da, Sherman et al. 2009, Huang da, Sherman et 
al. 2009) on the Affymetrix bovine background. Heat maps were generated using the 
heatmap.2 function from the gplots library in the R statistical environment (Team 2013, 
Gregory R. Warnes 2014). Probe set data were hierarchically clustered with complete 
linkage using the Euclidean metric.  
6.5 RT-qPCR  
 To confirm the microarray results, we performed RT-qPCR using SYBR® green assay 
(Bio-Rad Laboratories, Inc.) for a selected number of target genes. The RT-qPCR 
analysis was performed on 22 samples (from 7 control, 8 preclinical and 7 clinical 
animals). For each sample, 250 ng of total RNA were used as template for the cDNA 
synthesis with the SuperScript® III Reverse Transcriptase and the Oligo (dT)20 Primer 
(Life Technologies). PCR primers were designed using the online tool Primer-BLAST 
(Ye, Coulouris et al. 2012) provided by NCBI. Whenever possible, the primer pairs were 
designed in order to span an exon-exon junction, thus preventing the amplification of 
genomic DNA. The primer sequences were as follows: for GNLY 5’-AGC CCG ATG 
AGA ATA CCG TT and 5’- CGA TGT CCT CAG CGA TGG TA; for CD40L 5’-ACA ACC 
TCT GTT CTC CAG TG and 5’-GCT GTT TCC CGT TTT CGA GG; for PDK4 5’-TGG 
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TGT TCC CCT GAG AGT CA and 5’-GTA ACC AAA ACC AGC CAG CG; for HBA2 5’- 
ACA AGG GCA ATG TCA AGG CC and 5’- TCG AAG TGG GGG AAG TAG GT; for 
XIST 5’-GTG GCA AGG ACC AGA ATG GA and 5’-TCC GAC CCC AGT ATT AGC CA; 
for GNB4 5’-AGA TCG TGC AGG TGT TCT TG and 5’-CTG TCC CAA GAC CCT GTT 
G; for IDO1 5’-ATT GGT GGA GTC CCT GCA GAC and 5’-CTG CAG GGT AGC ATT 
GCC TT; for BOLA 5’CTC GTA GTA GCT GTG GTG GC and 5’ACT GTC ACT GCT 
TGC AGC C; for SEL1L3 5’-TGA AGG AGT GGTTTC GCC TG and 5’ TTC AAA TCC 
TGC CCA GTG CT; for RPL12 5’-AGG GTC TGA GGA TTA CAG TGA AA and 5’-GAT 
CAG GGC AGA AGC AGA AGG; for ACTB 5’-GGA CTT CGA GCA GGA GAT GG and 
5’-TTC CAT GCC CAG GAA GGA AG; for GAPDH 5’-AGG TCG GAG TGA ACG GAT 
TC and 5’-ATG GCG ACG ATG TCC ACT TT. The RT-qPCR reactions were carried out 
by denaturing at 95 °C for 15s, annealing at 60 °C for 1 min and extension at 55 °C for 1 
min for 45 cycles. Melt curve analysis and gel electrophoresis of amplification products 
were performed for each primer pair to confirm the production of a single PCR 
amplicon. The amplification was performed using a CFX96™ Real-Time PCR Detection 
System (Bio-Rad Laboratories, Inc.). All the RT-qPCR reactions were run in triplicate 
and included the following controls: no template (NTC) and minus-reverse transcriptase 
(RT-) negative controls. The normalization accuracy was improved by geometric 
averaging of multiple reference genes (Vandesompele, De Preter et al. 2002) and using 
two inter-run calibrators to reduce inter-run variation. We decided to use a normalization 
factor based on three reference genes (GAPDH, RPL12 and ACTB) since it has been 
shown in the literature that this is the minimal number required for a reliable 
normalization (Lyahyai, Serrano et al. 2010). Stability of the selected reference genes 
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was determined by calculating their geNorm M value (M) and the coefficient of variation 
(CV) on the normalized relative quantities (Hellemans, Mortier et al. 2007). M and CV 
values were then compared against empirically determined thresholds for acceptable 
stability (~ 1 and ~ 0.5 for M and CV values respectively) (Hellemans, Mortier et al. 
2007) (see Figure 10). The statistical analysis and the fold change calculation were 
carried out using qBasePlus 1.1 software (Hellemans, Mortier et al. 2007). 
 
Availability of supporting data 
 
The data sets supporting the results of this article are available in the Gene Expression 
Omnibus (GEO) repository: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=mzgxuaagddwftcz&acc=GSE690
48. The DEGs were analyzed for their functions, pathways and networks using DAVID 
Bioinformatic Tool 6.7 (NIAID/NIH, USA). 
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